<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article article-type="research-article" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0146195</article-id>
<article-id pub-id-type="publisher-id">PONE-D-15-41255</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Prognostic Value of <sup>18</sup>F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis</article-title>
<alt-title alt-title-type="running-head">FDG PET and Prognosis of Surgical NSCLC</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Liu</surname>
<given-names>Jing</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Dong</surname>
<given-names>Min</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Sun</surname>
<given-names>Xiaorong</given-names>
</name>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Li</surname>
<given-names>Wenwu</given-names>
</name>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Xing</surname>
<given-names>Ligang</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Yu</surname>
<given-names>Jinming</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Radiation Oncology and Shandong Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Oncology, the People’s Hospital of Pingyi County, Pingyi, Shandong, China</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Department of Radiology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Patnaik</surname>
<given-names>Santosh</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Roswell Park Cancer Institute, UNITED STATES</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con" id="contrib001">
<p>Conceived and designed the experiments: LX JY JL. Performed the experiments: JL MD XS WL LX JY. Analyzed the data: JL MD XS WL LX. Contributed reagents/materials/analysis tools: JL MD XS LX JY. Wrote the paper: JL MD LX.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">xinglg@medmail.com.cn</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>4</day>
<month>1</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>11</volume>
<issue>1</issue>
<elocation-id>e0146195</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>9</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>12</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-year>2016</copyright-year>
<copyright-holder>Liu et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0146195"/>
<abstract>
<sec id="sec001">
<title>Background</title>
<p>The identification of surgical non-small cell lung cancer (NSCLC) patients with poor prognosis is a priority in clinical oncology because of their high 5-year mortality. This meta-analysis explored the prognostic value of maximal standardized uptake value (SUV<sub>max</sub>), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) on disease-free survival (DFS) and overall survival (OS) in surgical NSCLC patients.</p>
</sec>
<sec id="sec002">
<title>Materials and Methods</title>
<p>MEDLINE, EMBASE and Cochrane Libraries were systematically searched until August 1, 2015. Prospective or retrospective studies that evaluated the prognostic roles of preoperative 18F-FDG PET/CT with complete DFS and OS data in surgical NSCLC patients were included. The impact of SUV<sub>max</sub>, MTV or TLG on survival was measured using hazard ratios (HR). Sub-group analyses were performed based on disease stage, pathological classification, surgery only and cut-off values.</p>
</sec>
<sec id="sec003">
<title>Results</title>
<p>Thirty-six studies comprised of 5807 patients were included. The combined HRs for DFS were 2.74 (95%CI 2.33–3.24, unadjusted) and 2.43 (95%CI: 1.76–3.36, adjusted) for SUV<sub>max</sub>, 2.27 (95%CI 1.77–2.90, unadjusted) and 2.49 (95%CI 1.23–5.04, adjusted) for MTV, and 2.46 (95%CI 1.91–3.17, unadjusted) and 2.97 (95%CI 1.68–5.28, adjusted) for TLG. The pooled HRs for OS were 2.54 (95%CI 1.86–3.49, unadjusted) and 1.52 (95%CI 1.16–2.00, adjusted) for SUV<sub>max</sub>, 2.07 (95%CI 1.16–3.69, unadjusted) and 1.91 (95%CI 1.13–3.22, adjusted) for MTV, and 2.47 (95%CI 1.38–4.43, unadjusted) and 1.94 (95%CI 1.12–3.33, adjusted) for TLG. Begg’s test detected publication bias, the trim and fill procedure was performed, and similar HRs were obtained. The prognostic role of SUV<sub>max</sub>, MTV and TLG remained similar in the sub-group analyses.</p>
</sec>
<sec id="sec004">
<title>Conclusions</title>
<p>High values of SUV<sub>max</sub>, MTV and TLG predicted a higher risk of recurrence or death in patients with surgical NSCLC. We suggest the use of FDG PET/CT to select patients who are at high risk of disease recurrence or death and may benefit from aggressive treatments.</p>
</sec>
</abstract>
<funding-group>
<funding-statement>This work was supported in part by the grant from National Health and Family Planning Commission Institutes of the People’s Republic of China (201402011), and the grants from National Natural Science Foundation of China (81272502 and L1322016) to LX. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="4"/>
<table-count count="4"/>
<page-count count="19"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p>The application of advanced diagnostic and screening techniques led to the increased detection of early staged non-small cell lung cancers (NSCLC) and improved cures using standard surgery [<xref ref-type="bibr" rid="pone.0146195.ref001">1</xref>]. The 5-year survival after resection of localized NSCLC approaches a modest 50% despite improved surgical techniques and advanced adjuvant therapy [<xref ref-type="bibr" rid="pone.0146195.ref002">2</xref>, <xref ref-type="bibr" rid="pone.0146195.ref003">3</xref>]. No prognostic factor, except stage and performance status, was definitively established in NSCLC. Accurate markers would be invaluable to stratify patients for adjuvant therapy and predict outcomes.</p>
<p><sup>18</sup>F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is the standard modality for staging, treatment response monitoring and prognosis prediction for a variety of tumors, including NSCLC [<xref ref-type="bibr" rid="pone.0146195.ref004">4</xref>, <xref ref-type="bibr" rid="pone.0146195.ref005">5</xref>]. Standardized uptake value (SUV) is a semi-quantitative determination of the normalized concentration of radioactivity, and maximum SUV (SUV<sub>max</sub>) is the most widely applied parameter in clinical practice [<xref ref-type="bibr" rid="pone.0146195.ref006">6</xref>]. Volumetric parameters, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG), were also used recently to reflect disease burden and tumor aggressiveness in NSCLC [<xref ref-type="bibr" rid="pone.0146195.ref004">4</xref>, <xref ref-type="bibr" rid="pone.0146195.ref007">7</xref>]. Several recent systematic reviews and meta-analyses [<xref ref-type="bibr" rid="pone.0146195.ref008">8</xref>–<xref ref-type="bibr" rid="pone.0146195.ref010">10</xref>] found that SUV was negatively correlated with prognosis in heterogeneous groups of NSCLC patients. Im et al. [<xref ref-type="bibr" rid="pone.0146195.ref011">11</xref>] reported significant prognostic values of MTV and TLG on survival in NSCLC patients. However, the quality of existing studies has not been systematically assessed, and their clinical features have not been fully assessed to further evaluate the potential association between SUV or volumetric parameters and prognosis in surgical NSCLC.</p>
<p>Therefore, we performed a meta-analysis to identify, appraise, and synthesize results from published studies that examined the prognostic value of SUV<sub>max</sub>, MTV and TLG on disease-free survival (DFS) and overall survival (OS) in surgical NSCLC patients.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="sec007">
<title>Search Strategy and Eligible Criteria</title>
<p>MEDLINE, EMBASE and Cochrane Library were searched and updated through August 1, 2015. The following terms were used: “non-small cell lung cancer” OR “NSCLC” OR “carcinoma, non-small cell lung” AND “<sup>18</sup>F-FDG” OR “fluorodeoxyglucose” OR “PET” OR “positron emission tomography” AND “survival” OR “local control” OR “prognostic” OR “outcome” OR “predict” AND “surgery” OR “resect” OR “operation”. Reviews, case studies, conference abstracts and editorials were excluded.</p>
<p>Two authors independently searched articles and performed an initial screening of identified titles and abstracts. Articles were further reviewed if they reported the prognosis of surgically resected NSCLC patients with pre-operative <sup>18</sup>F-FDG PET/CT imaging from original data. Full-text articles were used for the second screening. The following inclusion criteria for the meta-analysis were used: (1) prospective or retrospective studies investigating the correlation of FDG uptake with DFS, recurrence-free survival (RFS), and/or OS; (2) pathological stage I-IIIA NSCLC patients who received diagnostic <sup>18</sup>F-FDG PET/CT scanning before treatments; (3) treated with surgery alone or adjuvant therapy; (4) survival data assessed in detail; and (5) surgical procedures included either full anatomical resections or limited lung resection regardless of whether they were performed via open thoracotomy or video-assisted thoracic surgery. A consensus resolved any discrepancies.</p>
<p>Studies that included patients with small cell lung cancer (SCLC) were eligible if more than 95% of patients had NSCLC. Patients with an advanced stage (IIIB-IV) also accounted for less than 5% of the included studies. Data were partially extracted when only certain sub-group analyses met our inclusion criteria. Studies that included patients who received neoadjuvant therapy were excluded. Only the most recent or complete report was included when the survival results of the same patient population were reported more than once.</p>
</sec>
<sec id="sec008">
<title>Data Extraction</title>
<p>Data extraction was conducted in agreement with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance (<xref ref-type="supplementary-material" rid="pone.0146195.s001">S1 PRISMA Checklist</xref>) [<xref ref-type="bibr" rid="pone.0146195.ref012">12</xref>]. Two investigators independently extracted information, including the first author, publication year, country, study design, sample size, stage, treatment, and survival endpoints. The primary endpoint was DFS, which was measured from the defined starting point in each study to the date of recurrence or first progression. OS was taken as the secondary endpoint and defined as the time from the starting point applied in each study to death.</p>
</sec>
<sec id="sec009">
<title>Study Quality Control</title>
<p>Three investigators reviewed and scored each article independently using a quality scale (<xref ref-type="supplementary-material" rid="pone.0146195.s002">S1 File</xref>). Quality assessment included four modified parts based on similar studies: scientific design, the generalizability of the results, data analyses, and PET reports [<xref ref-type="bibr" rid="pone.0146195.ref013">13</xref>–<xref ref-type="bibr" rid="pone.0146195.ref015">15</xref>]. Five items were observed in each part. A point value of 0, 1, or 2 was scored to each item. A consensus was obtained of all investigators present, which ensured the objectivity of the scores and correct interpretation. Final scores are expressed as percentages, and higher values reflect a greater consistence with quality assessment standards. Any article with a final score &lt; 60% was excluded.</p>
</sec>
<sec id="sec010">
<title>Statistical Analysis</title>
<p>Review Manager statistical software (RevMan, version 5.3) was used. The impact of SUV<sub>max</sub>, MTV and TLG on DFS and OS was measured using hazard ratios (HRs). Survival data were extracted using the methodology suggested by Tierney et al. [<xref ref-type="bibr" rid="pone.0146195.ref016">16</xref>]. Cut-off values of SUV<sub>max</sub>, MTV and TLG and the delineation thresholds applied to MTV and TLG were determined based on the definition applied in each individual study. Unadjusted and adjusted values were extracted for risk measurements. We extracted the HR estimate and 95% confidence intervals (CIs) directly from each study when provided by the authors. <italic>P</italic> values of the log-rank test, number analyzed in each group, and the number of events were extracted to estimate the univariate HR indirectly. Correlations between the quality scores and the number of patients were measured using the Spearman’s rank correlation coefficient.</p>
<p>Heterogeneity was evaluated using Cochrane’s Q test and <italic>I</italic><sup><italic>2</italic></sup> [<xref ref-type="bibr" rid="pone.0146195.ref017">17</xref>]. <italic>P</italic>&lt;0.05 in Q test was considered significant heterogeneity. An <italic>I</italic><sup><italic>2</italic></sup> value of 0% indicates no heterogeneity, a value less than 25% indicates low heterogeneity, a value of 25.1–50% indicates moderate heterogeneity, and a value greater than 50% indicates substantial heterogeneity [<xref ref-type="bibr" rid="pone.0146195.ref018">18</xref>]. A fixed effect model was used to calculate the pooled HRs when no, low or moderate heterogeneity was observed. A random effects model was applied when substantial or significant heterogeneity was observed. An HR greater than 1 implied worse survival outcome for patients with high SUV<sub>max</sub>, MTV or TLG, but an HR less than 1 implied a survival benefit for patients with high SUV<sub>max</sub>, MTV or TLG. Sub-group analyses were performed based on histological subtypes, pathological stage, surgery only and cut-off values.</p>
<p>The possibility of publication bias was estimated using visual inspection of a funnel plot. Begg’s test was performed for meta-analysis that included more than 10 studies [<xref ref-type="bibr" rid="pone.0146195.ref019">19</xref>, <xref ref-type="bibr" rid="pone.0146195.ref020">20</xref>]. We also performed non-parametric “trim and fill” procedures to further estimate the potential influence of publication bias [<xref ref-type="bibr" rid="pone.0146195.ref021">21</xref>, <xref ref-type="bibr" rid="pone.0146195.ref022">22</xref>]. This procedure calculates a new pooled HR that incorporates hypothetical missing studies.</p>
</sec>
</sec>
<sec id="sec011" sec-type="results">
<title>Results</title>
<sec id="sec012">
<title>Study Characteristics and Qualitative Assessment</title>
<p>Thirty-six eligible studies were included in the meta-analysis [<xref ref-type="bibr" rid="pone.0146195.ref023">23</xref>–<xref ref-type="bibr" rid="pone.0146195.ref058">58</xref>] (<xref ref-type="fig" rid="pone.0146195.g001">Fig 1</xref>, Tables <xref ref-type="table" rid="pone.0146195.t001">1</xref> and <xref ref-type="table" rid="pone.0146195.t002">2</xref>). Only two studies [<xref ref-type="bibr" rid="pone.0146195.ref031">31</xref>, <xref ref-type="bibr" rid="pone.0146195.ref037">37</xref>] were prospectively designed. The studies were published between 2000 and 2015, and the sample size varied from 49 to 530 subjects (median 102). Only 5 SCLC [<xref ref-type="bibr" rid="pone.0146195.ref040">40</xref>, <xref ref-type="bibr" rid="pone.0146195.ref051">51</xref>] patients were mixed into the analysis of 5807 patients. Four studies lacked raw data of stage [<xref ref-type="bibr" rid="pone.0146195.ref023">23</xref>, <xref ref-type="bibr" rid="pone.0146195.ref029">29</xref>, <xref ref-type="bibr" rid="pone.0146195.ref040">40</xref>, <xref ref-type="bibr" rid="pone.0146195.ref049">49</xref>], but the distribution of stages I, II, III and IV were 80.4%, 14.2%, 4.5% (2.7% IIIA, 0.9% IIIB, and 0.9% stage III) and 0.9%, respectively. <xref ref-type="table" rid="pone.0146195.t001">Table 1</xref> lists PET/CT scans and models. The dose of FDG injected varied from 150 to 666 MBq based on different individual scanning protocols. The time duration before scanning was 40–60 minutes in 28 studies, 81 minutes in 1 study, 90 minutes in 1 study and not reported in 6 studies. SUV<sub>max</sub> was measured in 34 studies [<xref ref-type="bibr" rid="pone.0146195.ref023">23</xref>–<xref ref-type="bibr" rid="pone.0146195.ref025">25</xref>, <xref ref-type="bibr" rid="pone.0146195.ref028">28</xref>–<xref ref-type="bibr" rid="pone.0146195.ref058">58</xref>], which normalized values by body weight. MTV was measured in 7 studies [<xref ref-type="bibr" rid="pone.0146195.ref024">24</xref>, <xref ref-type="bibr" rid="pone.0146195.ref026">26</xref>–<xref ref-type="bibr" rid="pone.0146195.ref029">29</xref>, <xref ref-type="bibr" rid="pone.0146195.ref052">52</xref>, <xref ref-type="bibr" rid="pone.0146195.ref053">53</xref>], and TLG was measured in 7 studies [<xref ref-type="bibr" rid="pone.0146195.ref024">24</xref>, <xref ref-type="bibr" rid="pone.0146195.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0146195.ref027">27</xref>, <xref ref-type="bibr" rid="pone.0146195.ref029">29</xref>, <xref ref-type="bibr" rid="pone.0146195.ref052">52</xref>, <xref ref-type="bibr" rid="pone.0146195.ref053">53</xref>, <xref ref-type="bibr" rid="pone.0146195.ref056">56</xref>]. A fixed SUV of 2.5 [<xref ref-type="bibr" rid="pone.0146195.ref027">27</xref>, <xref ref-type="bibr" rid="pone.0146195.ref028">28</xref>, <xref ref-type="bibr" rid="pone.0146195.ref052">52</xref>, <xref ref-type="bibr" rid="pone.0146195.ref056">56</xref>], the gradient segmentation method [<xref ref-type="bibr" rid="pone.0146195.ref029">29</xref>], a 50% of SUV<sub>max</sub> [<xref ref-type="bibr" rid="pone.0146195.ref024">24</xref>], a 42% of SUV<sub>max</sub> [<xref ref-type="bibr" rid="pone.0146195.ref053">53</xref>], and mediastinal background SUV<sub>mean</sub> plus 2 standard deviations [<xref ref-type="bibr" rid="pone.0146195.ref026">26</xref>] were adapted to segment volumes of interest. A minimum <italic>P</italic> value, receiver operating characteristics (ROCs), and median value were applied in most studies to determine cut-off values. Median cut-off points were 5.90 (2.4 to 20) for SUV<sub>max</sub>. The cut-off values of MTV were between 2.95 and 37.34 cm<sup>3</sup> (median 11.197 for OS and 10.29 for DFS), and TLG values ranged from 9.61 to 407.48 (median 26.739 for OS and 29.221 for DFS).</p>
<fig id="pone.0146195.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0146195.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Flowchart of Study Selection.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0146195.g001" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0146195.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0146195.t001</object-id>
<label>Table 1</label> <caption><title>Studies Included in Meta-Analysis.</title></caption>
<alternatives>
<graphic id="pone.0146195.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0146195.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2">Study</th>
<th align="left" rowspan="2">Year</th>
<th align="left" rowspan="2">Country</th>
<th align="left" rowspan="2">Study design</th>
<th align="left" rowspan="2">No. of patients</th>
<th align="left" rowspan="2">TNM staging</th>
<th align="left" rowspan="2">Treatment</th>
<th align="left" rowspan="2">Endpoints</th>
<th align="left" rowspan="2">PET scanners</th>
<th align="left" rowspan="2">PET parameters</th>
<th align="left" rowspan="2">Tumor delineation (thresholds)</th>
<th align="left" rowspan="2">Determination of cut-off values</th>
<th align="left" colspan="3">Cut-off values</th>
</tr>
<tr>
<th align="left">SUV</th>
<th align="left">MTV (cm<sup>3</sup>)</th>
<th align="left">TLG</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Cistaro et al. [<xref ref-type="bibr" rid="pone.0146195.ref023">23</xref>]</td>
<td align="left">2013</td>
<td align="left">Italy</td>
<td align="left">R</td>
<td align="left">49</td>
<td align="left">I-II</td>
<td align="left">Surgery</td>
<td align="left">DFS</td>
<td align="left">Discovery ST, GE</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">Minimum P value method</td>
<td align="left">9.0</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Melloni et al. [<xref ref-type="bibr" rid="pone.0146195.ref024">24</xref>]</td>
<td align="left">2013</td>
<td align="left">Italy</td>
<td align="left">R</td>
<td align="left">99</td>
<td align="left">I</td>
<td align="left">Surgery</td>
<td align="left">DFS</td>
<td align="left">Discovery STE or Discovery 690, GE; GEMINI-GXL, Philips</td>
<td align="left">SUV<sub>max</sub> /MTV/TLG</td>
<td align="left">50%SUV<sub>max</sub></td>
<td align="left">Median</td>
<td align="left">2.73</td>
<td align="left">2.95</td>
<td align="left">9.61</td>
</tr>
<tr>
<td align="left">Ohtaka et al. [<xref ref-type="bibr" rid="pone.0146195.ref025">25</xref>]</td>
<td align="left">2013</td>
<td align="left">Japan</td>
<td align="left">R</td>
<td align="left">191</td>
<td align="left">I-IIIA</td>
<td align="left">Surgery</td>
<td align="left">OS/DFS</td>
<td align="left">ECAT EXACT HR+, Siemens</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">Median</td>
<td align="left">2.4</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Hyun et al. [<xref ref-type="bibr" rid="pone.0146195.ref026">26</xref>]</td>
<td align="left">2013</td>
<td align="left">Korea</td>
<td align="left">R</td>
<td align="left">529</td>
<td align="left">I-II</td>
<td align="left">Surgery ± adjuvant CT/RT/CRT</td>
<td align="left">OS/DFS</td>
<td align="left">Discovery LS, GE</td>
<td align="left">MTV/TLG</td>
<td align="left">Mediastinal background SUV<sub>mean</sub> plus 2 standard deviations</td>
<td align="left">ROC curve</td>
<td align="left"/>
<td align="left">16</td>
<td align="left">70</td>
</tr>
<tr>
<td align="left">Kim et al. [<xref ref-type="bibr" rid="pone.0146195.ref027">27</xref>]</td>
<td align="left">2012</td>
<td align="left">Korea</td>
<td align="left">R</td>
<td align="left">91</td>
<td align="left">I-IIIA</td>
<td align="left">Surgery ± adjuvant CT</td>
<td align="left">OS/RFS</td>
<td align="left">Gemini, Philips; Biograph40, Siemens</td>
<td align="left">MTV/TLG</td>
<td align="left">SUV2.5</td>
<td align="left">ROC curve</td>
<td align="left"/>
<td align="left">11.613/9.598</td>
<td align="left">13.797/18.762</td>
</tr>
<tr>
<td align="left">Lin et al. [<xref ref-type="bibr" rid="pone.0146195.ref028">28</xref>]</td>
<td align="left">2012</td>
<td align="left">Taiwan</td>
<td align="left">R</td>
<td align="left">60</td>
<td align="left">I</td>
<td align="left">Surgery</td>
<td align="left">DFS</td>
<td align="left">Discovery STE, GE</td>
<td align="left">SUV<sub>max</sub>/MTV</td>
<td align="left">SUV2.5</td>
<td align="left">Median</td>
<td align="left">2.5</td>
<td align="left">9.8</td>
<td align="left"/>
</tr>
<tr>
<td align="left">Zhang et al. [<xref ref-type="bibr" rid="pone.0146195.ref029">29</xref>]</td>
<td align="left">2013</td>
<td align="left">China</td>
<td align="left">R</td>
<td align="left">59</td>
<td align="left">I-IV</td>
<td align="left">Surgery</td>
<td align="left">OS</td>
<td align="left">Reveal HD, CTI</td>
<td align="left">SUV<sub>max</sub> /MTV/TLG</td>
<td align="left">Gradient tumor segmentation</td>
<td align="left">ROC curve</td>
<td align="left">11.59</td>
<td align="left">37.34</td>
<td align="left">407.48</td>
</tr>
<tr>
<td align="left">Agarwal et al. [<xref ref-type="bibr" rid="pone.0146195.ref030">30</xref>]</td>
<td align="left">2010</td>
<td align="left">USA</td>
<td align="left">R</td>
<td align="left">363</td>
<td align="left">I-II</td>
<td align="left">Surgery</td>
<td align="left">OS</td>
<td align="left">Discovery DST or Advance, GE</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">Median</td>
<td align="left">5.9</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Dooms et al. [<xref ref-type="bibr" rid="pone.0146195.ref031">31</xref>]</td>
<td align="left">2009</td>
<td align="left">Belgium</td>
<td align="left">P</td>
<td align="left">91</td>
<td align="left">I-II</td>
<td align="left">Surgery</td>
<td align="left">OS</td>
<td align="left">931/08/12 or ECAT EXACT 922, CTI-Siemens</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">Median</td>
<td align="left">NR</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Goodgame et al. [<xref ref-type="bibr" rid="pone.0146195.ref032">32</xref>]</td>
<td align="left">2008</td>
<td align="left">USA</td>
<td align="left">R</td>
<td align="left">136</td>
<td align="left">I</td>
<td align="left">Surgery</td>
<td align="left">Recurrence rate/OS</td>
<td align="left">ECAT EXACT or Biograph LSO Duo hybrid PET/CT, Siemens; ADAC CPET-Plus, Phillips</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">Median</td>
<td align="left">5.5</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Hanin et al. [<xref ref-type="bibr" rid="pone.0146195.ref033">33</xref>]</td>
<td align="left">2008</td>
<td align="left">Belgium</td>
<td align="left">R</td>
<td align="left">96</td>
<td align="left">I-II</td>
<td align="left">Surgery</td>
<td align="left">OS/DFS</td>
<td align="left">ECAT HR+, Siemens</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">Median</td>
<td align="left">7.8</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Kim et al. [<xref ref-type="bibr" rid="pone.0146195.ref034">34</xref>]</td>
<td align="left">2011</td>
<td align="left">Korea</td>
<td align="left">R</td>
<td align="left">76</td>
<td align="left">I-II</td>
<td align="left">Surgery</td>
<td align="left">OS/DFS</td>
<td align="left">Gemini, Philips</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">ROC curve</td>
<td align="left">6.7/5.9</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Nair et al. [<xref ref-type="bibr" rid="pone.0146195.ref035">35</xref>]</td>
<td align="left">2010</td>
<td align="left">USA</td>
<td align="left">R</td>
<td align="left">75</td>
<td align="left">IA</td>
<td align="left">Surgery</td>
<td align="left">OS</td>
<td align="left">CTI</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">Minimum P value method</td>
<td align="left">5</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Um et al. [<xref ref-type="bibr" rid="pone.0146195.ref036">36</xref>]</td>
<td align="left">2009</td>
<td align="left">Korea</td>
<td align="left">R</td>
<td align="left">145</td>
<td align="left">I</td>
<td align="left">Surgery</td>
<td align="left">DFS</td>
<td align="left">Discovery LS, GE</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">ROC curve</td>
<td align="left">13.1</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Vesselle et al. [<xref ref-type="bibr" rid="pone.0146195.ref037">37</xref>]</td>
<td align="left">2007</td>
<td align="left">USA</td>
<td align="left">P</td>
<td align="left">103</td>
<td align="left">I-III</td>
<td align="left">Surgery</td>
<td align="left">OS/DFS</td>
<td align="left">PET Advance, GE</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">Minimum P value method</td>
<td align="left">7</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Zhang et al. [<xref ref-type="bibr" rid="pone.0146195.ref038">38</xref>]</td>
<td align="left">2007</td>
<td align="left">China</td>
<td align="left">R</td>
<td align="left">82</td>
<td align="left">I-III</td>
<td align="left">Surgery ± adjuvant CT</td>
<td align="left">OS/DFS</td>
<td align="left">Discovery LS, GE</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">Median</td>
<td align="left">11</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Bille et al. [<xref ref-type="bibr" rid="pone.0146195.ref039">39</xref>]</td>
<td align="left">2013</td>
<td align="left">UK</td>
<td align="left">R</td>
<td align="left">404</td>
<td align="left">I-IV</td>
<td align="left">Surgery ± adjuvant CT</td>
<td align="left">OS</td>
<td align="left">Discovery ST, GE</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">Median</td>
<td align="left">8.6</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Dhital et al. [<xref ref-type="bibr" rid="pone.0146195.ref040">40</xref>]</td>
<td align="left">2000</td>
<td align="left">UK</td>
<td align="left">R</td>
<td align="left">77</td>
<td align="left">I-IIIA</td>
<td align="left">Surgery</td>
<td align="left">OS</td>
<td align="left">ECAT 951/31R, Siemens</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">Minimum P value method</td>
<td align="left">20</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Higashi et al. [<xref ref-type="bibr" rid="pone.0146195.ref041">41</xref>]</td>
<td align="left">2002</td>
<td align="left">Japan</td>
<td align="left">R</td>
<td align="left">57</td>
<td align="left">I-III</td>
<td align="left">Surgery</td>
<td align="left">OS/DFS</td>
<td align="left">Headtome IV, Shimazu</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">Minimum P value method</td>
<td align="left">5</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Kim et al. [<xref ref-type="bibr" rid="pone.0146195.ref042">42</xref>]</td>
<td align="left">2009</td>
<td align="left">Korea</td>
<td align="left">R</td>
<td align="left">107</td>
<td align="left">I</td>
<td align="left">Surgery</td>
<td align="left">DFS</td>
<td align="left">Allegro, Philips</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">Median</td>
<td align="left">2.4</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Ohtsuka et al. [<xref ref-type="bibr" rid="pone.0146195.ref043">43</xref>]</td>
<td align="left">2006</td>
<td align="left">Japan</td>
<td align="left">R</td>
<td align="left">98</td>
<td align="left">I</td>
<td align="left">Surgery</td>
<td align="left">DFS</td>
<td align="left">NR</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">ROC curve</td>
<td align="left">3.3</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Stiles et al. [<xref ref-type="bibr" rid="pone.0146195.ref044">44</xref>]</td>
<td align="left">2013</td>
<td align="left">USA</td>
<td align="left">R</td>
<td align="left">530</td>
<td align="left">I-IIIA</td>
<td align="left">Surgery</td>
<td align="left">DFS</td>
<td align="left">NR</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">Median</td>
<td align="left">4.8</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Tomita et al. [<xref ref-type="bibr" rid="pone.0146195.ref045">45</xref>]</td>
<td align="left">2012</td>
<td align="left">Japan</td>
<td align="left">R</td>
<td align="left">197</td>
<td align="left">I-III</td>
<td align="left">Surgery</td>
<td align="left">OS</td>
<td align="left">Siemens</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">Median</td>
<td align="left">6.6</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Tsutani et al. [<xref ref-type="bibr" rid="pone.0146195.ref046">46</xref>]</td>
<td align="left">2011</td>
<td align="left">Japan</td>
<td align="left">R</td>
<td align="left">176</td>
<td align="left">I-III</td>
<td align="left">Surgery</td>
<td align="left">DFS</td>
<td align="left">Discovery ST16, GE</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">ROC curve</td>
<td align="left">3.7/6.95</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">van Baardwijk et al. [<xref ref-type="bibr" rid="pone.0146195.ref047">47</xref>]</td>
<td align="left">2007</td>
<td align="left">Netherlands</td>
<td align="left">R</td>
<td align="left">102</td>
<td align="left">I-III</td>
<td align="left">Surgery</td>
<td align="left">OS</td>
<td align="left">931/08/12 or ECAT EXACT 922, CTI-Siemens</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">Minimum P value method</td>
<td align="left">8/11</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Downey et al. [<xref ref-type="bibr" rid="pone.0146195.ref048">48</xref>]</td>
<td align="left">2007</td>
<td align="left">UK</td>
<td align="left">R</td>
<td align="left">487</td>
<td align="left">I-IV</td>
<td align="left">Surgery</td>
<td align="left">OS</td>
<td align="left">NR</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">Median</td>
<td align="left">5.3</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Koo et al. [<xref ref-type="bibr" rid="pone.0146195.ref049">49</xref>]</td>
<td align="left">2011</td>
<td align="left">Korea</td>
<td align="left">R</td>
<td align="left">75</td>
<td align="left">I-II</td>
<td align="left">Surgery</td>
<td align="left">DFS</td>
<td align="left">Gemini, Philips</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">ROC curve</td>
<td align="left">4.5</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Pelosi et al. [<xref ref-type="bibr" rid="pone.0146195.ref050">50</xref>]</td>
<td align="left">2011</td>
<td align="left">Italy</td>
<td align="left">R</td>
<td align="left">153</td>
<td align="left">I-IV</td>
<td align="left">Surgery ± adjuvant CT</td>
<td align="left">OS/DFS</td>
<td align="left">Discovery ST, GE</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">Minimum P value method</td>
<td align="left">9</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Shiono et al. [<xref ref-type="bibr" rid="pone.0146195.ref051">51</xref>]</td>
<td align="left">2011</td>
<td align="left">Japan</td>
<td align="left">R</td>
<td align="left">201</td>
<td align="left">I</td>
<td align="left">Surgery ± adjuvant CT</td>
<td align="left">DFS</td>
<td align="left">Discovery LS, GE</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">ROC curve</td>
<td align="left">4.7</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Kim et al. [<xref ref-type="bibr" rid="pone.0146195.ref052">52</xref>]</td>
<td align="left">2014</td>
<td align="left">Korea</td>
<td align="left">R</td>
<td align="left">102</td>
<td align="left">I-II</td>
<td align="left">Surgery</td>
<td align="left">DFS</td>
<td align="left">Reveal RT-HiREZ, CTI; Discovery STE, GE</td>
<td align="left">SUV<sub>max</sub> /MTV/TLG</td>
<td align="left">SUV2.5</td>
<td align="left">ROC curve</td>
<td align="left">6.90</td>
<td align="left">10.78</td>
<td align="left">39.68</td>
</tr>
<tr>
<td align="left">Domachevsky et al [<xref ref-type="bibr" rid="pone.0146195.ref053">53</xref>]</td>
<td align="left">2015</td>
<td align="left">Israel</td>
<td align="left">R</td>
<td align="left">181</td>
<td align="left">I-II</td>
<td align="left">Surgery</td>
<td align="left">OS</td>
<td align="left">Discovery STE, GE</td>
<td align="left">SUV<sub>max</sub> /MTV/TLG</td>
<td align="left">42%SUV<sub>max</sub></td>
<td align="left">Median</td>
<td align="left">8.2</td>
<td align="left">NR</td>
<td align="left">NR</td>
</tr>
<tr>
<td align="left">Ko et al [<xref ref-type="bibr" rid="pone.0146195.ref054">54</xref>]</td>
<td align="left">2015</td>
<td align="left">Taiwan</td>
<td align="left">R</td>
<td align="left">145</td>
<td align="left">IA</td>
<td align="left">Surgery</td>
<td align="left">RFS</td>
<td align="left">Biograph, Siemens</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">ROC curve</td>
<td align="left">2.5</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Motono et al [<xref ref-type="bibr" rid="pone.0146195.ref055">55</xref>]</td>
<td align="left">2014</td>
<td align="left">Japan</td>
<td align="left">R</td>
<td align="left">58</td>
<td align="left">I-IIIA</td>
<td align="left">Surgery</td>
<td align="left">DFS</td>
<td align="left">Headtome IV, Shimazu</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">NR</td>
<td align="left">NR</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Park et al [<xref ref-type="bibr" rid="pone.0146195.ref056">56</xref>]</td>
<td align="left">2015</td>
<td align="left">Korea</td>
<td align="left">R</td>
<td align="left">248</td>
<td align="left">IA</td>
<td align="left">Surgery</td>
<td align="left">OS</td>
<td align="left">Discovery 600, GE; Biograph TruePoint 40, Siemens</td>
<td align="left">SUV<sub>max</sub> /TLG</td>
<td align="left">SUV2.5</td>
<td align="left">Maximally selected rank</td>
<td align="left">3.7</td>
<td align="left"/>
<td align="left">13.76</td>
</tr>
<tr>
<td align="left">Shimizu et al [<xref ref-type="bibr" rid="pone.0146195.ref057">57</xref>]</td>
<td align="left">2014</td>
<td align="left">Japan</td>
<td align="left">R</td>
<td align="left">84</td>
<td align="left">I-III</td>
<td align="left">Surgery</td>
<td align="left">DFS</td>
<td align="left">Discovery ST, GE</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">ROC curve</td>
<td align="left">3.95/9.7</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Yoo et al [<xref ref-type="bibr" rid="pone.0146195.ref058">58</xref>]</td>
<td align="left">2014</td>
<td align="left">Korea</td>
<td align="left">R</td>
<td align="left">80</td>
<td align="left">I-IIA</td>
<td align="left">Surgery</td>
<td align="left">DFS</td>
<td align="left">Biographs; Siemens</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left"/>
<td align="left">Minimum P value method</td>
<td align="left">4</td>
<td align="left"/>
<td align="left"/>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p><bold>Abbreviations:</bold> T: tumor; N: lymph node; M: metastasis; PET: positron emission tomography; SUV: standardized uptake value; MTV: metabolic tumor volume; TLG: total lesion glycolysis; R: retrospective; P: prospective; DFS: disease-free survival; OS: overall survival; SUV<sub>max</sub>: maximal standardized uptake value; CT: chemotherapy; RT: radiotherapy; CRT: chemoradiotherapy; SUV<sub>mean</sub>: mean standardized uptake value; ROC: receiver operating characteristic; RFS: recurrence-free survival; NR: not reported.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="pone.0146195.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0146195.t002</object-id>
<label>Table 2</label> <caption><title>Clinical Characteristics of Included Studies.</title></caption>
<alternatives>
<graphic id="pone.0146195.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0146195.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Study Criteria</th>
<th align="left">No. of Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Study design</td>
<td align="left"/>
</tr>
<tr>
<td align="left">    Prospective design</td>
<td align="left">2</td>
</tr>
<tr>
<td align="left">    Retrospective design</td>
<td align="left">34</td>
</tr>
<tr>
<td align="left">Histology</td>
<td align="left"/>
</tr>
<tr>
<td align="left">    Adenocarcinoma only</td>
<td align="left">4</td>
</tr>
<tr>
<td align="left">    NSCLC</td>
<td align="left">30</td>
</tr>
<tr>
<td align="left">    NSCLC and SCLC</td>
<td align="left">2</td>
</tr>
<tr>
<td align="left">Treatment</td>
<td align="left"/>
</tr>
<tr>
<td align="left">    Surgery only</td>
<td align="left">30</td>
</tr>
<tr>
<td align="left">    Surgery ± adjuvant chemotherapy</td>
<td align="left">5</td>
</tr>
<tr>
<td align="left">    Surgery ± adjuvant chemotherapy/radiotherapy</td>
<td align="left">1</td>
</tr>
<tr>
<td align="left">Prognostic parameters</td>
<td align="left"/>
</tr>
<tr>
<td align="left">    SUV<sub>max</sub></td>
<td align="left">34</td>
</tr>
<tr>
<td align="left">    MTV</td>
<td align="left">7</td>
</tr>
<tr>
<td align="left">    TLG</td>
<td align="left">7</td>
</tr>
<tr>
<td align="left">Determination of cut-off values</td>
<td align="left"/>
</tr>
<tr>
<td align="left">    Minimum P value</td>
<td align="left">8</td>
</tr>
<tr>
<td align="left">    Receiver operating characteristics curve</td>
<td align="left">12</td>
</tr>
<tr>
<td align="left">    Median value</td>
<td align="left">14</td>
</tr>
<tr>
<td align="left">    Others</td>
<td align="left">2</td>
</tr>
<tr>
<td align="left">HR reported</td>
<td align="left"/>
</tr>
<tr>
<td align="left">    Adjusted</td>
<td align="left">25</td>
</tr>
<tr>
<td align="left">    Unadjusted</td>
<td align="left">35</td>
</tr>
<tr>
<td align="left">Multivariate analysis (with adjustment for)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">    Tumor stage</td>
<td align="left">14</td>
</tr>
<tr>
<td align="left">    Stage</td>
<td align="left">11</td>
</tr>
<tr>
<td align="left">    Age</td>
<td align="left">9</td>
</tr>
<tr>
<td align="left">    Gender</td>
<td align="left">6</td>
</tr>
<tr>
<td align="left">    Histology</td>
<td align="left">6</td>
</tr>
<tr>
<td align="left">    Lymph node status</td>
<td align="left">5</td>
</tr>
<tr>
<td align="left">    Differentiation</td>
<td align="left">5</td>
</tr>
<tr>
<td align="left">    Carcino-embryonic antigen level</td>
<td align="left">4</td>
</tr>
<tr>
<td align="left">Follow-up schedule</td>
<td align="left"/>
</tr>
<tr>
<td align="left">    Well-planned and described in detail</td>
<td align="left">11</td>
</tr>
<tr>
<td align="left">    Well-planned but not described in detail</td>
<td align="left">5</td>
</tr>
<tr>
<td align="left">    Not indicated</td>
<td align="left">20</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p><bold>Abbreviations:</bold> NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; SUV<sub>max</sub>: maximal standardized uptake value; MTV: metabolic tumor volume; TLG: total lesion glycolysis; DFS: disease-free survival; OS: overall survival; HR: hazard ratio; PET/CT: positron emission tomography/computed tomography.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Adjusted HRs were determined for 25 studies. Most risk measures were adjusted for tumor size or T stage, stage, age, gender and histology, and other studies were adjusted for lymph node status, differentiation and CEA level.</p>
<p>Twenty-seven studies published complete resection rates as 100%, while the remaining studies did not report rates. Average (mean or median) follow-up duration was given in 29 studies and ranged from 16.6 to 64 months (median 32.0 months). The follow-up design was reported in detail in 11 studies, but it was not indicated in 20 studies.</p>
<p>Attempts to contact the authors to obtain missing information of methodological quality were made when necessary, and the mean quality score was 77.5% (70.0% to 87.5%). Spearman’s correlation coefficient was 0.326 between the quality score and the number of patients (<italic>P</italic> = 0.36).</p>
</sec>
<sec id="sec013">
<title>Primary Outcome: DFS</title>
<p>Unadjusted analysis of SUV<sub>max</sub> and DFS (2845 patients) revealed a combined HR of 2.74 (95%CI: 2.33–3.24, <italic>P</italic> = 0.07, <italic>I</italic><sup><italic>2</italic></sup> = 32%) (<xref ref-type="fig" rid="pone.0146195.g002">Fig 2A</xref>). The funnel plots for publication bias exhibited significant asymmetry with statistical significance (Begg’s test, <italic>z</italic> = 3.59, <italic>P</italic>&lt;0.001). The pooled HR was 2.37 (95% CI: 2.03–2.75) after the trim and fill analysis (<xref ref-type="fig" rid="pone.0146195.g003">Fig 3A</xref>). Sensitively analysis was further conducted with significant heterogeneity (<italic>I</italic><sup><italic>2</italic></sup> = 72%, <italic>P</italic>&lt;0.00001, HR 2.43, 95%CI: 1.76–3.36) for multivariate analysis of SUV<sub>max</sub> and DFS (2279 patients) (<xref ref-type="fig" rid="pone.0146195.g002">Fig 2B</xref>) to estimate the effect of each study on the pooled HR by omitting one study at a time. Three studies [<xref ref-type="bibr" rid="pone.0146195.ref034">34</xref>, <xref ref-type="bibr" rid="pone.0146195.ref044">44</xref>, <xref ref-type="bibr" rid="pone.0146195.ref055">55</xref>] were omitted, and an HR of 3.24 (2.43–4.33) using a fixed-model was obtained with a decreased I<sup>2</sup> of 38% and a P value of 0.07 in the Q test. The Begg’s test was statistically significant (<italic>z</italic> = 2.23, <italic>P</italic> = 0.026). The pooled HR was 1.77 (95% CI: 1.29–2.43) after the trim and fill analysis (<xref ref-type="fig" rid="pone.0146195.g003">Fig 3B</xref>).</p>
<fig id="pone.0146195.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0146195.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Forest plots of HR for recurrence with SUV<sub>max</sub> (A, unadjusted; B, adjusted), MTV (C, unadjusted; D, adjusted) and TLG (E, unadjusted; F, adjusted).</title>
<p>The Chi<sup>2</sup> test is a measurement of heterogeneity. <italic>P</italic>&lt;0.05 indicates significant heterogeneity. Squares = individual study point estimates. Horizontal lines = 95% CIs. Rhombus = summarized estimate and its 95% CI. Fixed: fixed effect model. Random: random effect model.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0146195.g002" xlink:type="simple"/>
</fig>
<fig id="pone.0146195.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0146195.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Funnel plots without (left column) and with (right column) trim and fill.</title>
<p>The pseudo 95% confidence interval (CI) is computed as part of the analysis that produced the funnel plot and corresponds to the expected 95% CI for a given standard error (SE). HR indicates hazard ratio.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0146195.g003" xlink:type="simple"/>
</fig>
<p>Five studies (881 patients) indicated that a larger MTV predicted worse local control using univariate analysis with a pooled HR of 2.27 (95% CI: 1.77–2.90, <italic>P</italic> = 0.16, <italic>I</italic><sup><italic>2</italic></sup> = 39%) (<xref ref-type="fig" rid="pone.0146195.g002">Fig 2C</xref>). Three studies obtained the same result [<xref ref-type="bibr" rid="pone.0146195.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0146195.ref027">27</xref>, <xref ref-type="bibr" rid="pone.0146195.ref052">52</xref>] for multivariate analysis, and 1 study reported undetermined results [<xref ref-type="bibr" rid="pone.0146195.ref028">28</xref>]. The combined HR of all 4 studies (782 patients) was 2.49 (95% CI: 1.23–5.04, <italic>P</italic> = 0.04, <italic>I</italic><sup><italic>2</italic></sup> = 63%) (<xref ref-type="fig" rid="pone.0146195.g002">Fig 2D</xref>). High TLG was associated with poor local control in 4 studies (821 patients) using univariate analysis with a combined HR of 2.46 (95% CI: 1.91–3.17, <italic>P</italic> = 0.39, <italic>I</italic><sup><italic>2</italic></sup> = 1%) (<xref ref-type="fig" rid="pone.0146195.g002">Fig 2E</xref>). Multivariate analysis with 3 studies (730 patients) revealed a combined HR of 2.97 (95%CI: 1.68–5.28, <italic>P</italic> = 0.09, <italic>I</italic><sup><italic>2</italic></sup> = 59%) (<xref ref-type="fig" rid="pone.0146195.g002">Fig 2F</xref>).</p>
</sec>
<sec id="sec014">
<title>Secondary Outcome: OS</title>
<p>Univariate analysis of 19 studies (3178 patients) explored the prognostic role of SUV<sub>max</sub> for OS and demonstrated a combined HR of 2.54 (95%CI: 1.86–3.49, <italic>P</italic>&lt;0.00001, <italic>I</italic><sup><italic>2</italic></sup> = 86%) (<xref ref-type="fig" rid="pone.0146195.g004">Fig 4A</xref>). <italic>I</italic><sup><italic>2</italic></sup> was not statistically significant (17 studies, 2698 patients, <italic>P</italic> = 0.19, <italic>I</italic><sup><italic>2</italic></sup> = 23%) after the exclusion of two studies [<xref ref-type="bibr" rid="pone.0146195.ref034">34</xref>, <xref ref-type="bibr" rid="pone.0146195.ref039">39</xref>] with an HR of 2.26 (95%CI: 1.94–2.64). Begg’s test revealed no significant publication bias (<italic>z</italic> = 1.47, <italic>P</italic> = 0.141). Heterogeneity also existed (<italic>I</italic><sup><italic>2</italic></sup> = 68%, <italic>P</italic> = 0.002, HR = 1.52, 95%CI: 1.16–2.00) in adjusted analyses of SUV<sub>max</sub> and OS rate (9 studies, 1467 patients) (<xref ref-type="fig" rid="pone.0146195.g004">Fig 4B</xref>). Exclusion of the report from Bille et al.[<xref ref-type="bibr" rid="pone.0146195.ref039">39</xref>] reduced this heterogeneity and led to a <italic>P</italic> value of 0.69 (8 studies, 1063 patients, <italic>I</italic><sup><italic>2</italic></sup> = 0%). A fixed-effect model revealed that the combined HR reached 1.64 (95%CI: 1.34–1.99).</p>
<fig id="pone.0146195.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0146195.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Forest plots of HR for deaths with SUV<sub>max</sub> (A, unadjusted; B, adjusted), MTV (C, unadjusted; D, adjusted) and TLG (E, unadjusted; F, adjusted).</title>
<p>The Chi<sup>2</sup> test is a measurement of heterogeneity. <italic>P</italic>&lt;0.05 indicates significant heterogeneity. Squares = individual study point estimates. Horizontal lines = 95% CIs. Rhombus = summarized estimate and its 95%CI. Fixed: fixed effect model. Random: random effect model.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0146195.g004" xlink:type="simple"/>
</fig>
<p>Larger MTV predicted poor OS in univariate and multivariate analyses. Significant disparities were determined in unadjusted (4 studies, 860 patients, HR 2.07, 95%CI: 1.16–3.69, <italic>P</italic> = 0.005, <italic>I</italic><sup><italic>2</italic></sup> = 77%) and adjusted analyses (3 studies, 679 patients, HR = 1.91, 95%CI: 1.13–3.22, <italic>P</italic> = 0.11, <italic>I</italic><sup><italic>2</italic></sup> = 55%) (<xref ref-type="fig" rid="pone.0146195.g004">Fig 4C and 4D</xref>). High TLG was associated with poor OS in univariate analysis (5 studies, 1108 patients) with a combined HR of 2.47 (95%CI: 1.38–4.43, <italic>P</italic> = 0.0006, <italic>I</italic><sup><italic>2</italic></sup> = 79%). Multivariate analysis of 3 studies with 836 patients also demonstrated a significant prognostic role of TLG for OS (HR 1.94, 95%CI: 1.12–3.33, <italic>P</italic> = 0.04, <italic>I</italic><sup><italic>2</italic></sup> = 69%) (<xref ref-type="fig" rid="pone.0146195.g004">Fig 4E and 4F</xref>).</p>
</sec>
<sec id="sec015">
<title>Stratified Analyses of SUV<sub>max</sub></title>
<p><xref ref-type="table" rid="pone.0146195.t003">Table 3</xref> summarizes total and stratified results. The combined HRs of SUV<sub>max</sub> for stage I in the sub-group analysis for DFS according to disease stage were 3.62 (95%CI: 2.72–4.81, <italic>P</italic> = 0.07, <italic>I</italic><sup><italic>2</italic></sup> = 41%) from univariate analysis and 3.35 (95%CI: 2.18–5.16, <italic>P</italic> = 0.46, <italic>I</italic><sup><italic>2</italic></sup> = 0%) from multivariate analysis. Publication bias existed (Z = 2.81, P = 0.005) in univariate analysis, and the pooled HR was 3.00 (95%CI: 2.30–3.91) after the trim and fill process (<xref ref-type="fig" rid="pone.0146195.g003">Fig 3C</xref>). The combined HRs of SUV<sub>max</sub> from univariate analysis of stage I and stage II for OS were 3.43 (95%CI: 1.75–6.75, <italic>P</italic> = 0.01, <italic>I</italic><sup><italic>2</italic></sup> = 66%) and 2.64 (95%CI: 1.11–6.31, <italic>P</italic> = 0.23, <italic>I</italic><sup><italic>2</italic></sup> = 31%), respectively.</p>
<table-wrap id="pone.0146195.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0146195.t003</object-id>
<label>Table 3</label> <caption><title>Total and subgroup analyses of SUV<sub>max</sub>, MTV and TLG in surgical NSCLC.</title></caption>
<alternatives>
<graphic id="pone.0146195.t003g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0146195.t003" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Endpoint</th>
<th align="left">Parameter</th>
<th align="left">Factor</th>
<th align="left">Data source</th>
<th align="left">No. of studies</th>
<th align="left">HR</th>
<th align="left">95%CI of HR</th>
<th align="left">Heterogeneity, <italic>I</italic><sup><italic>2</italic></sup>(%)</th>
<th align="left">Model used</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">DFS</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left">Total</td>
<td align="left">Unadjusted</td>
<td align="left">22</td>
<td align="left">2.74</td>
<td align="left">2.33–3.24</td>
<td align="left">32</td>
<td align="left">Fixed</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">Adjusted</td>
<td align="left">17</td>
<td align="left">2.43</td>
<td align="left">1.76–3.36</td>
<td align="left">72</td>
<td align="left">Random</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left">Stage I</td>
<td align="left">Unadjusted</td>
<td align="left">11</td>
<td align="left">3.62</td>
<td align="left">2.72–4.81</td>
<td align="left">41</td>
<td align="left">Fixed</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">Adjusted</td>
<td align="left">6</td>
<td align="left">3.35</td>
<td align="left">2.18–5.16</td>
<td align="left">0</td>
<td align="left">Fixed</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left">ADC</td>
<td align="left">Unadjusted</td>
<td align="left">4</td>
<td align="left">4.81</td>
<td align="left">2.87–8.08</td>
<td align="left">47</td>
<td align="left">Fixed</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">Adjusted</td>
<td align="left">4</td>
<td align="left">2.92</td>
<td align="left">1.19–7.17</td>
<td align="left">77</td>
<td align="left">Random</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left">Non-ADC</td>
<td align="left">Unadjusted</td>
<td align="left">3</td>
<td align="left">1.98</td>
<td align="left">1.04–3.79</td>
<td align="left">0</td>
<td align="left">Fixed</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left">Surgery only</td>
<td align="left">Unadjusted</td>
<td align="left">19</td>
<td align="left">2.75</td>
<td align="left">2.30–3.29</td>
<td align="left">41</td>
<td align="left">Fixed</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">Adjusted</td>
<td align="left">15</td>
<td align="left">2.30</td>
<td align="left">1.65–3.20</td>
<td align="left">72</td>
<td align="left">Random</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left">Threshold ≤ 5.9</td>
<td align="left">Unadjusted</td>
<td align="left">14</td>
<td align="left">3.02</td>
<td align="left">2.42–3.77</td>
<td align="left">46</td>
<td align="left">Fixed</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">Adjusted</td>
<td align="left">11</td>
<td align="left">4.63</td>
<td align="left">2.53–8.48</td>
<td align="left">62</td>
<td align="left">Random</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left">Threshold &gt; 5.9</td>
<td align="left">Unadjusted</td>
<td align="left">10</td>
<td align="left">2.42</td>
<td align="left">1.89–3.11</td>
<td align="left">38</td>
<td align="left">Fixed</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">Adjusted</td>
<td align="left">7</td>
<td align="left">1.68</td>
<td align="left">1.07–2.63</td>
<td align="left">58</td>
<td align="left">Random</td>
</tr>
<tr>
<td align="left"/>
<td align="left">MTV</td>
<td align="left">Total</td>
<td align="left">Unadjusted</td>
<td align="left">5</td>
<td align="left">2.27</td>
<td align="left">1.77–2.90</td>
<td align="left">39</td>
<td align="left">Fixed</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">Adjusted</td>
<td align="left">4</td>
<td align="left">2.49</td>
<td align="left">1.23–5.04</td>
<td align="left">63</td>
<td align="left">Random</td>
</tr>
<tr>
<td align="left"/>
<td align="left">TLG</td>
<td align="left">Total</td>
<td align="left">Unadjusted</td>
<td align="left">4</td>
<td align="left">2.46</td>
<td align="left">1.91–3.17</td>
<td align="left">1</td>
<td align="left">Fixed</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">Adjusted</td>
<td align="left">3</td>
<td align="left">2.97</td>
<td align="left">1.68–5.28</td>
<td align="left">59</td>
<td align="left">Random</td>
</tr>
<tr>
<td align="left">OS</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left">Total</td>
<td align="left">Unadjusted</td>
<td align="left">19</td>
<td align="left">2.54</td>
<td align="left">1.86–3.49</td>
<td align="left">86</td>
<td align="left">Random</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">Adjusted</td>
<td align="left">9</td>
<td align="left">1.52</td>
<td align="left">1.16–2.00</td>
<td align="left">68</td>
<td align="left">Random</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left">Stage I</td>
<td align="left">Unadjusted</td>
<td align="left">6</td>
<td align="left">3.43</td>
<td align="left">1.75–6.75</td>
<td align="left">66</td>
<td align="left">Random</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">Adjusted</td>
<td align="left">2</td>
<td align="left">2.14</td>
<td align="left">1.21–3.77</td>
<td align="left">0</td>
<td align="left">Fixed</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left">Stage II</td>
<td align="left">Unadjusted</td>
<td align="left">3</td>
<td align="left">2.64</td>
<td align="left">1.11–6.31</td>
<td align="left">31</td>
<td align="left">Fixed</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left">Surgery only</td>
<td align="left">Unadjusted</td>
<td align="left">16</td>
<td align="left">2.27</td>
<td align="left">1.93–2.66</td>
<td align="left">48</td>
<td align="left">Fixed</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">Adjusted</td>
<td align="left">7</td>
<td align="left">1.59</td>
<td align="left">1.30–1.95</td>
<td align="left">0</td>
<td align="left">Fixed</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left">Threshold ≤ 5.9</td>
<td align="left">Unadjusted</td>
<td align="left">8</td>
<td align="left">3.47</td>
<td align="left">2.10–5.71</td>
<td align="left">68</td>
<td align="left">Random</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">Adjusted</td>
<td align="left">3</td>
<td align="left">1.61</td>
<td align="left">1.22–2.12</td>
<td align="left">0</td>
<td align="left">Fixed</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left">Threshold &gt; 5.9</td>
<td align="left">Unadjusted</td>
<td align="left">10</td>
<td align="left">2.12</td>
<td align="left">1.44–3.13</td>
<td align="left">85</td>
<td align="left">Random</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">Adjusted</td>
<td align="left">5</td>
<td align="left">1.42</td>
<td align="left">0.97–2.08</td>
<td align="left">67</td>
<td align="left">Random</td>
</tr>
<tr>
<td align="left"/>
<td align="left">MTV</td>
<td align="left">Total</td>
<td align="left">Unadjusted</td>
<td align="left">4</td>
<td align="left">2.07</td>
<td align="left">1.16–3.69</td>
<td align="left">77</td>
<td align="left">Random</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">Adjusted</td>
<td align="left">3</td>
<td align="left">1.91</td>
<td align="left">1.13–3.22</td>
<td align="left">55</td>
<td align="left">Random</td>
</tr>
<tr>
<td align="left"/>
<td align="left">TLG</td>
<td align="left">Total</td>
<td align="left">Unadjusted</td>
<td align="left">5</td>
<td align="left">2.47</td>
<td align="left">1.38–4.43</td>
<td align="left">79</td>
<td align="left">Random</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">Adjusted</td>
<td align="left">3</td>
<td align="left">1.94</td>
<td align="left">1.12–3.33</td>
<td align="left">69</td>
<td align="left">Random</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001"><p><bold>Abbreviations:</bold> SUV<sub>max</sub>: maximal standardized uptake value; MTV: metabolic tumor volume; TLG: total lesion glycolysis; NSCLC: non-small cell lung cancer; HR: hazard ratio; CI: confidence interval; DFS: disease-free survival; OS: overall survival; ADC: adenocarcinoma.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Sub-group analysis based on the histology type revealed that the combined HRs of SUV<sub>max</sub> on DFS from univariate analysis for adenocarcinoma and non-adenocarcinoma were 4.81 (95%CI: 2.87–8.08, <italic>P</italic> = 0.13, <italic>I</italic><sup><italic>2</italic></sup> = 47%) and 1.98 (95%CI: 1.04–3.79, <italic>P</italic> = 0.64, <italic>I</italic><sup><italic>2</italic></sup> = 0%), respectively. Four studies provided multivariate analysis of SUV<sub>max</sub> on DFS for adenocarcinoma patients, with a pooled HR of 2.92 (95%CI: 1.19–7.17, <italic>P</italic> = 0.005, <italic>I</italic><sup><italic>2</italic></sup> = 77%).</p>
<p>The combined HRs of SUV<sub>max</sub> on DFS were 2.75 (95%CI: 2.30–3.29, <italic>P</italic> = 0.03, <italic>I</italic><sup><italic>2</italic></sup> = 41%) and 2.30 (95%CI: 1.65–3.20, <italic>P</italic>&lt;0.01, <italic>I</italic><sup><italic>2</italic></sup> = 72%) in unadjusted and adjusted analysis, respectively, when analyses were narrowed to surgical only patients without adjuvant therapy. The pooled HRs of SUV<sub>max</sub> in univariate and multivariate analysis were 2.27 (95%CI: 1.93–2.66, <italic>P</italic> = 0.02, <italic>I</italic><sup><italic>2</italic></sup> = 48%) and 1.59 (95%CI: 1.30–1.95, <italic>P</italic> = 0.79, <italic>I</italic><sup><italic>2</italic></sup> = 0%), respectively, for OS.</p>
<p>Cut-off values of SUV<sub>max</sub> in each individual study were determined to be high (&gt;5.9) or low (&lt; = 5.9) based on the median value. Subgroup analyses demonstrated that the combined HRs of SUV<sub>max</sub> for high cut-off value were 2.42 (95%CI: 1.89–3.11, <italic>P</italic> = 0.10, <italic>I</italic><sup><italic>2</italic></sup> = 38%) from univariate analysis and 1.68 (95%CI: 1.07–2.63, <italic>P</italic> = 0.03, <italic>I</italic><sup><italic>2</italic></sup> = 58%) from multivariate analysis. The low cut-off value studies demonstrated that the combined HRs of SUV<sub>max</sub> (univariate analysis: HR 3.02, 95%CI: 2.42–3.77, <italic>P</italic> = 0.03, <italic>I</italic><sup><italic>2</italic></sup> = 46%; multivariate analysis: HR 4.63, 95%CI: 2.53–8.48, <italic>P</italic> = 0.003, <italic>I</italic><sup><italic>2</italic></sup> = 62%) were larger than the high cut-off value subgroup. Analysis of OS data also revealed a similar trend with pooled HRs of 3.47 (95%CI: 2.10–5.71, <italic>P</italic> = 0.003, <italic>I</italic><sup><italic>2</italic></sup> = 68%) and 1.61 (95%CI: 1.22–2.12, <italic>P</italic> = 0.38, <italic>I</italic><sup><italic>2</italic></sup> = 0%) for high cut-off group and 2.12 (95%CI: 1.44–3.13, <italic>P</italic>&lt;0.01, <italic>I</italic><sup><italic>2</italic></sup> = 85%) and 1.42 (95%CI: 0.97–2.08, <italic>P</italic> = 0.02, <italic>I</italic><sup><italic>2</italic></sup> = 67%) for low cut-off group in unadjusted and adjusted analyses, respectively.</p>
</sec>
</sec>
<sec id="sec016" sec-type="conclusions">
<title>Discussion</title>
<p>There is a high risk of local relapse and distant metastasis after curative resection for early-stage and localized NSCLC. Therefore, adjuvant therapy was explored to eliminate occult metastases and/or loco-regional residual tumor cells with a consequent reduction on recurrence and prolonged survival. It is essential to identify prognostic factors that may predict patients who are at a high risk of recurrence who will attain the most benefit from the adjuvant therapy to optimize the treatment. The evidence-based use of adjuvant therapy is highly dependent on clinical-pathological tumor staging information in the clinical setting. The role of <sup>18</sup>F-FDG PET/CT imaging for the prediction of local control and OS in surgical NSCLC must be investigated because it may provide important biological information beyond TNM staging. The present systemic review and meta-analysis found that higher values of SUV<sub>max</sub>, MTV and TLG predicted a higher risk of disease recurrence or death in patients with surgical NSCLC. The positive association remained statistically significant across stratified analyses according to stage, pathology and cut-off values. FDG PET/CT may be used to select patients who are at high risk of tumor recurrence or death and may benefit from subsequent more aggressive treatments.</p>
<p>SUV<sub>max</sub> is the most commonly used parameter in <sup>18</sup>F-FDG PET/CT diagnosis and response monitoring because of high reproducibility and availability. The potential prognostic value of SUV<sub>max</sub> for primary lung cancer was widely reported in various staged and treated populations [<xref ref-type="bibr" rid="pone.0146195.ref008">8</xref>–<xref ref-type="bibr" rid="pone.0146195.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0146195.ref014">14</xref>] (<xref ref-type="table" rid="pone.0146195.t004">Table 4</xref>). Therefore, our meta-analysis focused on surgical NSCLC only and provided the most comprehensive information for the total population and sub-groups based on disease stage, pathological classification and cut-off values. However, SUV<sub>max</sub> only provides information about a single volumetric pixel within the tumor, and it does not measure the volume or heterogeneity of metabolically active disease. Volumetric parameters, such as MTV and TLG, were investigated recently. The prognostic role of MTV and TLG was meta-analyzed in NSCLC patients with different stages [<xref ref-type="bibr" rid="pone.0146195.ref011">11</xref>]. Similar results were derived in our study, which focused on surgical NSCLC patients. Volume-based parameters exhibit advantages in the measurement of metabolic tumor burden, but controversy on the most appropriate segmentation method to measure MTV and TLG remains. Potential preferable performance of volumetric parameters to SUV<sub>max</sub> as prognostic factors were reported by the studies [<xref ref-type="bibr" rid="pone.0146195.ref024">24</xref>, <xref ref-type="bibr" rid="pone.0146195.ref028">28</xref>, <xref ref-type="bibr" rid="pone.0146195.ref029">29</xref>, <xref ref-type="bibr" rid="pone.0146195.ref052">52</xref>, <xref ref-type="bibr" rid="pone.0146195.ref053">53</xref>] that reported complete data of FDG PET/CT-derived parameters. The present meta-analysis demonstrated that SUV<sub>max</sub> performed equally with volumetric parameters based on existing data because of the limited data of volumetric parameters compared with FDG uptake. Other FDG PET/CT imaging characteristics beyond traditional parameters were also studied, such as intratumor FDG uptake heterogeneity. This parameter, as an area under the curve (AUC) of the cumulative histogram, and texture analysis predict tumor control [<xref ref-type="bibr" rid="pone.0146195.ref059">59</xref>] and are independent prognostic factors for survival [<xref ref-type="bibr" rid="pone.0146195.ref060">60</xref>–<xref ref-type="bibr" rid="pone.0146195.ref062">62</xref>] in NSCLC. However, these reports were not included in present meta-analysis because the study population was relatively small.</p>
<table-wrap id="pone.0146195.t004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0146195.t004</object-id>
<label>Table 4</label> <caption><title>Previous meta-analyses of 18F-FDG PET/CT on survival of NSCLC patients.</title></caption>
<alternatives>
<graphic id="pone.0146195.t004g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0146195.t004" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Study</th>
<th align="left">Year</th>
<th align="left">Stage</th>
<th align="left">Treatment</th>
<th align="left">No. of studies</th>
<th align="left">No. of patients</th>
<th align="left">Endpoints</th>
<th align="left">PET parameters</th>
<th align="left">HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Na et al. [<xref ref-type="bibr" rid="pone.0146195.ref008">8</xref>]</td>
<td align="left">2014</td>
<td align="left">I-IV</td>
<td align="left">Radiotherapy</td>
<td align="left">13</td>
<td align="left">1081</td>
<td align="left">OS/LC</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left">OS: 1.05 (1.02–1.08) LC: 1.26 (1.05–1.52)</td>
</tr>
<tr>
<td align="left">Nair et al. [<xref ref-type="bibr" rid="pone.0146195.ref009">9</xref>]</td>
<td align="left">2009</td>
<td align="left">I</td>
<td align="left">Surgery</td>
<td align="left">9</td>
<td align="left">1166</td>
<td align="left">OS/DFS</td>
<td align="left">SUV<sub>max</sub>/SUV<sub>mean</sub></td>
<td align="left">NA</td>
</tr>
<tr>
<td align="left">Paesmans et al. [<xref ref-type="bibr" rid="pone.0146195.ref010">10</xref>]</td>
<td align="left">2010</td>
<td align="left">I-IV</td>
<td align="left">Any</td>
<td align="left">24</td>
<td align="left">2638</td>
<td align="left">OS/DFS</td>
<td align="left">SUV</td>
<td align="left">2.08 (1.69–2.56)</td>
</tr>
<tr>
<td align="left">Im et al. [<xref ref-type="bibr" rid="pone.0146195.ref011">11</xref>]</td>
<td align="left">2014</td>
<td align="left">I-IV</td>
<td align="left">Any</td>
<td align="left">13</td>
<td align="left">1581</td>
<td align="left">OS/EFS</td>
<td align="left">MTV</td>
<td align="left">OS: 2.31 (1.54–3.47) EFS: 2.71 (1.82–4.02)</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">TLG</td>
<td align="left">OS: 2.43 (1.89–3.11) EFS: 2.35 (1.91–2.89)</td>
</tr>
<tr>
<td align="left">Berghmans et al. [<xref ref-type="bibr" rid="pone.0146195.ref014">14</xref>]</td>
<td align="left">2008</td>
<td align="left">I-IV</td>
<td align="left">Any</td>
<td align="left">13</td>
<td align="left">1474</td>
<td align="left">OS</td>
<td align="left">SUV<sub>max</sub></td>
<td align="left">2.27 (1.70–3.02)</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t004fn001"><p><bold>Abbreviations:</bold> FDG: fluorodeoxyglucose; PET/CT: positron emission tomography/computed tomography; NSCLC: non-small cell lung cancer; HR: hazard ratio; OS: overall survival; LC: local control; SUV<sub>max</sub>: maximal standardized uptake value; SUV<sub>mean</sub>: mean standardized uptake value; NA: not available; MTV: metabolic tumor volume; TLG: total lesion glycolysis; DFS: disease-free survival; EFS: event-free survival.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Patient heterogeneity, statistical data mining, retrospective cohorts, PET acquisition and calculations of SUV<sub>max</sub> are significant contributors to heterogeneity, which limited the application of glucose uptake as a companion diagnostic/prognostic marker. NSCLC is a heterogeneous disease. Patients with different histological types, stages, surgical procedures and adjuvant treatments were included in the meta-analysis. For example, Higashi et al. [<xref ref-type="bibr" rid="pone.0146195.ref041">41</xref>] and Stiles et al. [<xref ref-type="bibr" rid="pone.0146195.ref044">44</xref>] applied similar thresholds for FDG uptake. Significant differences were found in Higashi’s study in DFS (HR 8.17, 95%CI: 2.83–23.53), but statistically significant differences in DFS were not found in Stiles’s study (HR 1.54, 95%CI: 0.92–2.56). There were more patients with stage I NSCLC (80.7% versus 76.8%) and more patients with bronchioloalveolar cell carcinoma (22.8% of BAC versus &lt;8.3%) in Higashi’s study, which may explain the lower risk of recurrence in patients with low tumor FDG uptake. The heterogeneity in PET imaging thresholds was also obvious between the studies, which be explained by many factors, including the type of PET machine, the algorithms for iteration and reconstruction, the time elapsed between FDG injection and emission scan, and the method for threshold determination. Differences in defining the regions of interest [<xref ref-type="bibr" rid="pone.0146195.ref063">63</xref>] and timing of the data acquisition [<xref ref-type="bibr" rid="pone.0146195.ref064">64</xref>] may also result in different absolute SUV estimates.</p>
<p>Heterogeneity between the included reports was the main limitation of this meta-analysis. Non-English articles were excluded. The fact that small sample studies with negative results are less frequently published or published with simple descriptions led to the phenomenon of increased standard error for higher HRs. The trim and fill sensitivity analysis in the present study, which incorporates the hypothetical missing studies, did not change the general result, which suggests that the association was convincible. Individual HRs from small sample studies weighed less in the total HR, and it was also helpful to ensure the reliability of results. MTV and TLG were measured in 7 studies only. Multivariate analyses were based on 5 studies for MTV and 4 for TLG. Too little data were available to meta-analyze the values of volumetric PET/CT parameters for the prediction of patient’s prognosis. Only 2 included studies were prospectively designed, but PET as a biomarker to prognosticate or predict the response to therapy was assessed over 10 years. The prospectively designed studies [<xref ref-type="bibr" rid="pone.0146195.ref065">65</xref>, <xref ref-type="bibr" rid="pone.0146195.ref066">66</xref>] that were ineligible for the present meta-analysis also reported primarily positive results on various FDG PET/CT-derived parameters of lung cancer patients. Our meta-analysis offers a considerably valid conclusion for clinical practice under the circumstance of insufficient evidence from prospectively designed data.</p>
<p>In summary, this meta-analysis demonstrated that high values of SUV<sub>max</sub> and MTV derived from the pretreatment of <sup>18</sup>F-FDG PET/CT predicted a higher risk of recurrence or death in surgical NSCLC patients. Our findings suggest that FDG PET/CT may be used for risk stratification in disease control and survival. Patients with tumors who exhibit intense FDG uptake may be considered at a high risk of treatment failure and may benefit from more aggressive treatment. Further individual patient data should be meta-analyzed to determine the optimal threshold for PET imaging parameters.</p>
</sec>
<sec id="sec017">
<title>Supporting Information</title>
<supplementary-material id="pone.0146195.s001" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pone.0146195.s001" xlink:type="simple">
<label>S1 PRISMA Checklist</label>
<caption>
<title>PRISMA checklist.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0146195.s002" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0146195.s002" xlink:type="simple">
<label>S1 File</label>
<caption>
<title>The quality scale used in this study.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pone.0146195.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zheng</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Schipper</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kidwell</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Reddy</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Ren</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis</article-title>. <source>International journal of radiation oncology, biology, physics</source>. <year>2014</year>;<volume>90</volume>(<issue>3</issue>):<fpage>603</fpage>–<lpage>11</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ijrobp.2014.05.055" xlink:type="simple">10.1016/j.ijrobp.2014.05.055</ext-link></comment> <object-id pub-id-type="pmid">25052562</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Goldstraw</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Crowley</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Chansky</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Giroux</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Groome</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Rami-Porta</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours</article-title>. <source>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer</source>. <year>2007</year>;<volume>2</volume>(<issue>8</issue>):<fpage>706</fpage>–<lpage>14</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/JTO.0b013e31812f3c1a" xlink:type="simple">10.1097/JTO.0b013e31812f3c1a</ext-link></comment> <object-id pub-id-type="pmid">17762336</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Naruke</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Tsuchiya</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Kondo</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Asamura</surname> <given-names>H</given-names></name>. <article-title>Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience</article-title>. <source>The Annals of thoracic surgery</source>. <year>2001</year>;<volume>71</volume>(<issue>6</issue>):<fpage>1759</fpage>–<lpage>64</lpage>. <object-id pub-id-type="pmid">11426744</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moon</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Hyun</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Choi</surname> <given-names>JY</given-names></name>. <article-title>Prognostic significance of volume-based PET parameters in cancer patients</article-title>. <source>Korean journal of radiology: official journal of the Korean Radiological Society</source>. <year>2013</year>;<volume>14</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>12</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3348/kjr.2013.14.1.1" xlink:type="simple">10.3348/kjr.2013.14.1.1</ext-link></comment> <object-id pub-id-type="pmid">23323025</object-id>; PubMed Central PMCID: PMC3542291.</mixed-citation></ref>
<ref id="pone.0146195.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhu</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Shim</surname> <given-names>H</given-names></name>. <article-title>Metabolic positron emission tomography imaging in cancer detection and therapy response</article-title>. <source>Seminars in oncology</source>. <year>2011</year>;<volume>38</volume>(<issue>1</issue>):<fpage>55</fpage>–<lpage>69</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1053/j.seminoncol.2010.11.012" xlink:type="simple">10.1053/j.seminoncol.2010.11.012</ext-link></comment> <object-id pub-id-type="pmid">21362516</object-id>; PubMed Central PMCID: PMC3075495.</mixed-citation></ref>
<ref id="pone.0146195.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Paidpally</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Chirindel</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Lam</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Agrawal</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Quon</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Subramaniam</surname> <given-names>RM</given-names></name>. <article-title>FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma</article-title>. <source>Imaging in medicine</source>. <year>2012</year>;<volume>4</volume>(<issue>6</issue>):<fpage>633</fpage>–<lpage>47</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2217/iim.12.60" xlink:type="simple">10.2217/iim.12.60</ext-link></comment> <object-id pub-id-type="pmid">23482696</object-id>; PubMed Central PMCID: PMC3587845.</mixed-citation></ref>
<ref id="pone.0146195.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Davison</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Mercier</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Russo</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Subramaniam</surname> <given-names>RM</given-names></name>. <article-title>PET-based primary tumor volumetric parameters and survival of patients with non-small cell lung carcinoma</article-title>. <source>AJR American journal of roentgenology</source>. <year>2013</year>;<volume>200</volume>(<issue>3</issue>):<fpage>635</fpage>–<lpage>40</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2214/AJR.12.9138" xlink:type="simple">10.2214/AJR.12.9138</ext-link></comment> <object-id pub-id-type="pmid">23436855</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Na</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Deng</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Xue</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Lu</surname> <given-names>Y</given-names></name>. <article-title>Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis</article-title>. <source>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer</source>. <year>2014</year>;<volume>9</volume>(<issue>6</issue>):<fpage>834</fpage>–<lpage>42</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/JTO.0000000000000185" xlink:type="simple">10.1097/JTO.0000000000000185</ext-link></comment> <object-id pub-id-type="pmid">24787963</object-id>; PubMed Central PMCID: PMC4219540.</mixed-citation></ref>
<ref id="pone.0146195.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nair</surname> <given-names>VS</given-names></name>, <name name-style="western"><surname>Krupitskaya</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Gould</surname> <given-names>MK</given-names></name>. <article-title>Positron emission tomography 18F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: a systematic review</article-title>. <source>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer</source>. <year>2009</year>;<volume>4</volume>(<issue>12</issue>):<fpage>1473</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/JTO.0b013e3181bccbc6" xlink:type="simple">10.1097/JTO.0b013e3181bccbc6</ext-link></comment> <object-id pub-id-type="pmid">19887967</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Paesmans</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Berghmans</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Dusart</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Garcia</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Hossein-Foucher</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Lafitte</surname> <given-names>JJ</given-names></name>, <etal>et al</etal>. <article-title>Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project</article-title>. <source>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer</source>. <year>2010</year>;<volume>5</volume>(<issue>5</issue>):<fpage>612</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/JTO.0b013e3181d0a4f5" xlink:type="simple">10.1097/JTO.0b013e3181d0a4f5</ext-link></comment> <object-id pub-id-type="pmid">20234323</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Im</surname> <given-names>HJ</given-names></name>, <name name-style="western"><surname>Pak</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Cheon</surname> <given-names>GJ</given-names></name>, <name name-style="western"><surname>Kang</surname> <given-names>KW</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>IJ</given-names></name>, <etal>et al</etal>. <article-title>Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis</article-title>. <source>European journal of nuclear medicine and molecular imaging</source>. <year>2015</year>;<volume>42</volume>(<issue>2</issue>):<fpage>241</fpage>–<lpage>51</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00259-014-2903-7" xlink:type="simple">10.1007/s00259-014-2903-7</ext-link></comment> <object-id pub-id-type="pmid">25193652</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moher</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Liberati</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tetzlaff</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>Group</surname> <given-names>P</given-names></name>. <article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title>. <source>PLoS medicine</source>. <year>2009</year>;<volume>6</volume>(<issue>7</issue>):<fpage>e1000097</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.1000097" xlink:type="simple">10.1371/journal.pmed.1000097</ext-link></comment> <object-id pub-id-type="pmid">19621072</object-id>; PubMed Central PMCID: PMC2707599.</mixed-citation></ref>
<ref id="pone.0146195.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pak</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Cheon</surname> <given-names>GJ</given-names></name>, <name name-style="western"><surname>Nam</surname> <given-names>HY</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Kang</surname> <given-names>KW</given-names></name>, <name name-style="western"><surname>Chung</surname> <given-names>JK</given-names></name>, <etal>et al</etal>. <article-title>Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Head and Neck Cancer: A Systematic Review and Meta-Analysis</article-title>. <source>Journal of nuclear medicine: official publication, Society of Nuclear Medicine</source>. <year>2014</year>;<volume>55</volume>(<issue>6</issue>):<fpage>884</fpage>–<lpage>90</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2967/jnumed.113.133801" xlink:type="simple">10.2967/jnumed.113.133801</ext-link></comment> <object-id pub-id-type="pmid">24752671</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Berghmans</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Dusart</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Paesmans</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Hossein-Foucher</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Buvat</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Castaigne</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project</article-title>. <source>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer</source>. <year>2008</year>;<volume>3</volume>(<issue>1</issue>):<fpage>6</fpage>–<lpage>12</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/JTO.0b013e31815e6d6b" xlink:type="simple">10.1097/JTO.0b013e31815e6d6b</ext-link></comment> <object-id pub-id-type="pmid">18166834</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pan</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Gu</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Xue</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>S</given-names></name>. <article-title>Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis</article-title>. <source>European journal of gastroenterology &amp; hepatology</source>. <year>2009</year>;<volume>21</volume>(<issue>9</issue>):<fpage>1008</fpage>–<lpage>15</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/MEG.0b013e328323d6fa" xlink:type="simple">10.1097/MEG.0b013e328323d6fa</ext-link></comment></mixed-citation></ref>
<ref id="pone.0146195.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tierney</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Stewart</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Ghersi</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Burdett</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sydes</surname> <given-names>MR</given-names></name>. <article-title>Practical methods for incorporating summary time-to-event data into meta-analysis</article-title>. <source>Trials</source>. <year>2007</year>;<volume>8</volume>:<fpage>16</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1745-6215-8-16" xlink:type="simple">10.1186/1745-6215-8-16</ext-link></comment> <object-id pub-id-type="pmid">17555582</object-id>; PubMed Central PMCID: PMC1920534.</mixed-citation></ref>
<ref id="pone.0146195.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dinnes</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Deeks</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kirby</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Roderick</surname> <given-names>P</given-names></name>. <article-title>A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy</article-title>. <source>Health Technol Assess</source>. <year>2005</year>;<volume>9</volume>(<issue>12</issue>):<fpage>1</fpage>–<lpage>113</lpage>, iii. <object-id pub-id-type="pmid">15774235</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Higgins</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>SG</given-names></name>, <name name-style="western"><surname>Deeks</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name>. <article-title>Measuring inconsistency in meta-analyses</article-title>. <source>BMJ</source>. <year>2003</year>;<volume>327</volume>(<issue>7414</issue>):<fpage>557</fpage>–<lpage>60</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/bmj.327.7414.557" xlink:type="simple">10.1136/bmj.327.7414.557</ext-link></comment> <object-id pub-id-type="pmid">12958120</object-id>; PubMed Central PMCID: PMC192859.</mixed-citation></ref>
<ref id="pone.0146195.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Davey</surname> <given-names>Smith G</given-names></name>, <name name-style="western"><surname>Schneider</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Minder</surname> <given-names>C</given-names></name>. <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source>. <year>1997</year>;<volume>315</volume>(<issue>7109</issue>):<fpage>629</fpage>–<lpage>34</lpage>. <object-id pub-id-type="pmid">9310563</object-id>; PubMed Central PMCID: PMC2127453.</mixed-citation></ref>
<ref id="pone.0146195.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname> <given-names>M</given-names></name>. <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source>. <year>1994</year>;<volume>50</volume>(<issue>4</issue>):<fpage>1088</fpage>–<lpage>101</lpage>. <object-id pub-id-type="pmid">7786990</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Higgins</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>SG</given-names></name>. <article-title>Quantifying heterogeneity in a meta-analysis</article-title>. <source>Statistics in medicine</source>. <year>2002</year>;<volume>21</volume>(<issue>11</issue>):<fpage>1539</fpage>–<lpage>58</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/sim.1186" xlink:type="simple">10.1002/sim.1186</ext-link></comment> <object-id pub-id-type="pmid">12111919</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Duval</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Tweedie</surname> <given-names>R</given-names></name>. <article-title>Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis</article-title>. <source>Biometrics</source>. <year>2000</year>;<volume>56</volume>(<issue>2</issue>):<fpage>455</fpage>–<lpage>63</lpage>. <object-id pub-id-type="pmid">10877304</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cistaro</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Quartuccio</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Mojtahedi</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Fania</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Filosso</surname> <given-names>PL</given-names></name>, <name name-style="western"><surname>Campenni</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Prediction of 2 years-survival in patients with stage I and II non-small cell lung cancer utilizing (18)F-FDG PET/CT SUV quantification</article-title>. <source>Radiology and oncology</source>. <year>2013</year>;<volume>47</volume>(<issue>3</issue>):<fpage>219</fpage>–<lpage>23</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2478/raon-2013-0023" xlink:type="simple">10.2478/raon-2013-0023</ext-link></comment> <object-id pub-id-type="pmid">24133385</object-id>; PubMed Central PMCID: PMC3794876.</mixed-citation></ref>
<ref id="pone.0146195.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Melloni</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Gajate</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Sestini</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Gallivanone</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Bandiera</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Landoni</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer</article-title>. <source>European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology</source>. <year>2013</year>;<volume>39</volume>(<issue>11</issue>):<fpage>1254</fpage>–<lpage>61</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ejso.2013.07.092" xlink:type="simple">10.1016/j.ejso.2013.07.092</ext-link></comment> <object-id pub-id-type="pmid">23948705</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ohtaka</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Hida</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Kaga</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Okamoto</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Shiga</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Tamaki</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Outcome analysis of (18)F-fluorodeoxyglucose positron-emission tomography in patients with lung cancer after partial volume correction</article-title>. <source>Anticancer research</source>. <year>2013</year>;<volume>33</volume>(<issue>11</issue>):<fpage>5193</fpage>–<lpage>8</lpage>. <object-id pub-id-type="pmid">24222169</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hyun</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Choi</surname> <given-names>JY</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Shim</surname> <given-names>YM</given-names></name>, <name name-style="western"><surname>Um</surname> <given-names>SW</given-names></name>, <etal>et al</etal>. <article-title>Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection</article-title>. <source>Annals of surgery</source>. <year>2013</year>;<volume>257</volume>(<issue>2</issue>):<fpage>364</fpage>–<lpage>70</lpage>. Epub 2012/09/13. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/SLA.0b013e318262a6ec" xlink:type="simple">10.1097/SLA.0b013e318262a6ec</ext-link></comment> <object-id pub-id-type="pmid">22968069</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kim</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>IJ</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>YS</given-names></name>, <name name-style="western"><surname>Pak</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>H</given-names></name>. <article-title>Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer</article-title>. <source>Nuclear medicine communications</source>. <year>2012</year>;<volume>33</volume>(<issue>6</issue>):<fpage>613</fpage>–<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/MNM.0b013e328351d4f5" xlink:type="simple">10.1097/MNM.0b013e328351d4f5</ext-link></comment> <object-id pub-id-type="pmid">22407127</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lin</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>WY</given-names></name>, <name name-style="western"><surname>Kao</surname> <given-names>CH</given-names></name>, <name name-style="western"><surname>Yen</surname> <given-names>KY</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>SW</given-names></name>, <name name-style="western"><surname>Yeh</surname> <given-names>JJ</given-names></name>. <article-title>Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer</article-title>. <source>Anticancer research</source>. <year>2012</year>;<volume>32</volume>(<issue>11</issue>):<fpage>5087</fpage>–<lpage>91</lpage>. <object-id pub-id-type="pmid">23155285</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhang</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Wroblewski</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Liao</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kampalath</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Penney</surname> <given-names>BC</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer</article-title>. <source>Academic radiology</source>. <year>2013</year>;<volume>20</volume>(<issue>1</issue>):<fpage>32</fpage>–<lpage>40</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.acra.2012.07.002" xlink:type="simple">10.1016/j.acra.2012.07.002</ext-link></comment> <object-id pub-id-type="pmid">22999369</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Agarwal</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Brahmanday</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Bajaj</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Ravikrishnan</surname> <given-names>KP</given-names></name>, <name name-style="western"><surname>Wong</surname> <given-names>CY</given-names></name>. <article-title>Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ((18)F-FDG) positron emission tomography (PET) in early-stage (I &amp; II) non-small cell lung cancers (NSCLC)</article-title>. <source>European journal of nuclear medicine and molecular imaging</source>. <year>2010</year>;<volume>37</volume>(<issue>4</issue>):<fpage>691</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00259-009-1291-x" xlink:type="simple">10.1007/s00259-009-1291-x</ext-link></comment> <object-id pub-id-type="pmid">19915840</object-id>; PubMed Central PMCID: PMC2844956.</mixed-citation></ref>
<ref id="pone.0146195.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dooms</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>van Baardwijk</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Verbeken</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>van Suylen</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Stroobants</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>De Ruysscher</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer</article-title>. <source>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer</source>. <year>2009</year>;<volume>4</volume>(<issue>7</issue>):<fpage>822</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/JTO.0b013e3181a97df7" xlink:type="simple">10.1097/JTO.0b013e3181a97df7</ext-link></comment> <object-id pub-id-type="pmid">19487964</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Goodgame</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Pillot</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Shriki</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Meyers</surname> <given-names>BF</given-names></name>, <name name-style="western"><surname>Zoole</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer</article-title>. <source>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer</source>. <year>2008</year>;<volume>3</volume>(<issue>2</issue>):<fpage>130</fpage>–<lpage>4</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/JTO.0b013e318160c122" xlink:type="simple">10.1097/JTO.0b013e318160c122</ext-link></comment> <object-id pub-id-type="pmid">18303432</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hanin</surname> <given-names>FX</given-names></name>, <name name-style="western"><surname>Lonneux</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Cornet</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Noirhomme</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Coulon</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Distexhe</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Prognostic value of FDG uptake in early stage non-small cell lung cancer</article-title>. <source>European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery</source>. <year>2008</year>;<volume>33</volume>(<issue>5</issue>):<fpage>819</fpage>–<lpage>23</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ejcts.2008.02.005" xlink:type="simple">10.1016/j.ejcts.2008.02.005</ext-link></comment> <object-id pub-id-type="pmid">18374589</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kim</surname> <given-names>YS</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>YK</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>IJ</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>YD</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>MK</given-names></name>. <article-title>Prediction of survival and cancer recurrence using F-18 FDG PET/CT in patients with surgically resected early stage (Stage I and II) non-small cell lung cancer</article-title>. <source>Neoplasma</source>. <year>2011</year>;<volume>58</volume>(<issue>3</issue>):<fpage>245</fpage>–<lpage>50</lpage>. <object-id pub-id-type="pmid">21391742</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nair</surname> <given-names>VS</given-names></name>, <name name-style="western"><surname>Barnett</surname> <given-names>PG</given-names></name>, <name name-style="western"><surname>Ananth</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Gould</surname> <given-names>MK</given-names></name>, <article-title>Veterans Affairs Solitary Nodule Accuracy Project Cooperative Studies G. PET scan 18F-fluorodeoxyglucose uptake and prognosis in patients with resected clinical stage IA non-small cell lung cancer</article-title>. <source>Chest</source>. <year>2010</year>;<volume>137</volume>(<issue>5</issue>):<fpage>1150</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1378/chest.09-2356" xlink:type="simple">10.1378/chest.09-2356</ext-link></comment> <object-id pub-id-type="pmid">20038738</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Um</surname> <given-names>SW</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Koh</surname> <given-names>WJ</given-names></name>, <name name-style="western"><surname>Suh</surname> <given-names>GY</given-names></name>, <name name-style="western"><surname>Chung</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Kwon</surname> <given-names>OJ</given-names></name>, <etal>et al</etal>. <article-title>Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer</article-title>. <source>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer</source>. <year>2009</year>;<volume>4</volume>(<issue>11</issue>):<fpage>1331</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/JTO.0b013e3181b6be3e" xlink:type="simple">10.1097/JTO.0b013e3181b6be3e</ext-link></comment> <object-id pub-id-type="pmid">19701106</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vesselle</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Freeman</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Wiens</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Stern</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Nguyen</surname> <given-names>HQ</given-names></name>, <name name-style="western"><surname>Hawes</surname> <given-names>SE</given-names></name>, <etal>et al</etal>. <article-title>Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role</article-title>. <source>Clinical cancer research: an official journal of the American Association for Cancer Research</source>. <year>2007</year>;<volume>13</volume>(<issue>11</issue>):<fpage>3255</fpage>–<lpage>63</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1078-0432.CCR-06-1128" xlink:type="simple">10.1158/1078-0432.CCR-06-1128</ext-link></comment> <object-id pub-id-type="pmid">17545531</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhang</surname> <given-names>ZJ</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Meng</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Du</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer</article-title>. <source>Chinese medical journal</source>. <year>2007</year>;<volume>120</volume>(<issue>2</issue>):<fpage>125</fpage>–<lpage>31</lpage>. <object-id pub-id-type="pmid">17335654</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bille</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Okiror</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Skanjeti</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Errico</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Arena</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Penna</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>The prognostic significance of maximum standardized uptake value of primary tumor in surgically treated non-small-cell lung cancer patients: analysis of 413 cases</article-title>. <source>Clinical lung cancer</source>. <year>2013</year>;<volume>14</volume>(<issue>2</issue>):<fpage>149</fpage>–<lpage>56</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cllc.2012.04.007" xlink:type="simple">10.1016/j.cllc.2012.04.007</ext-link></comment> <object-id pub-id-type="pmid">22682667</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dhital</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Saunders</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Seed</surname> <given-names>PT</given-names></name>, <name name-style="western"><surname>O'Doherty</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Dussek</surname> <given-names>J</given-names></name>. <article-title>[(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer</article-title>. <source>European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery</source>. <year>2000</year>;<volume>18</volume>(<issue>4</issue>):<fpage>425</fpage>–<lpage>8</lpage>. <object-id pub-id-type="pmid">11024379</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Higashi</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Ueda</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Arisaka</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Sakuma</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Nambu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Oguchi</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer</article-title>. <source>Journal of nuclear medicine: official publication, Society of Nuclear Medicine</source>. <year>2002</year>;<volume>43</volume>(<issue>1</issue>):<fpage>39</fpage>–<lpage>45</lpage>. <object-id pub-id-type="pmid">11801701</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kim</surname> <given-names>HR</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>WW</given-names></name>, <name name-style="western"><surname>Jheon</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sung</surname> <given-names>SW</given-names></name>. <article-title>The significance of maximum standardized uptake values in patients with stage I pulmonary adenocarcinoma</article-title>. <source>European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery</source>. <year>2009</year>;<volume>35</volume>(<issue>4</issue>):<fpage>712</fpage>–<lpage>6</lpage>; discussion 6–7. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ejcts.2008.12.030" xlink:type="simple">10.1016/j.ejcts.2008.12.030</ext-link></comment> <object-id pub-id-type="pmid">19211260</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ohtsuka</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Nomori</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Watanabe</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kaji</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Naruke</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Suemasu</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma</article-title>. <source>Cancer</source>. <year>2006</year>;<volume>107</volume>(<issue>10</issue>):<fpage>2468</fpage>–<lpage>73</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/cncr.22268" xlink:type="simple">10.1002/cncr.22268</ext-link></comment> <object-id pub-id-type="pmid">17036361</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stiles</surname> <given-names>BM</given-names></name>, <name name-style="western"><surname>Nasar</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Mirza</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Paul</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>PC</given-names></name>, <name name-style="western"><surname>Port</surname> <given-names>JL</given-names></name>, <etal>et al</etal>. <article-title>Ratio of positron emission tomography uptake to tumor size in surgically resected non-small cell lung cancer</article-title>. <source>The Annals of thoracic surgery</source>. <year>2013</year>;<volume>95</volume>(<issue>2</issue>):<fpage>397</fpage>–<lpage>403</lpage>; discussion 4. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.athoracsur.2012.07.038" xlink:type="simple">10.1016/j.athoracsur.2012.07.038</ext-link></comment> <object-id pub-id-type="pmid">23000262</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tomita</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Shimizu</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Ayabe</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Onitsuka</surname> <given-names>T</given-names></name>. <article-title>Maximum SUV on positron emission tomography and serum CEA level as prognostic factors after curative resection for non-small cell lung cancer</article-title>. <source>Asia-Pacific journal of clinical oncology</source>. <year>2012</year>;<volume>8</volume>(<issue>3</issue>):<fpage>244</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1743-7563.2012.01549.x" xlink:type="simple">10.1111/j.1743-7563.2012.01549.x</ext-link></comment> <object-id pub-id-type="pmid">22897792</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tsutani</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Miyata</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Misumi</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Ikeda</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Mimura</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Hihara</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Difference in prognostic significance of maximum standardized uptake value on [18F]-fluoro-2-deoxyglucose positron emission tomography between adenocarcinoma and squamous cell carcinoma of the lung</article-title>. <source>Japanese journal of clinical oncology</source>. <year>2011</year>;<volume>41</volume>(<issue>7</issue>):<fpage>890</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jjco/hyr062" xlink:type="simple">10.1093/jjco/hyr062</ext-link></comment> <object-id pub-id-type="pmid">21613306</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van Baardwijk</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Dooms</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>van Suylen</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Verbeken</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Hochstenbag</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Dehing-Oberije</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer</article-title>. <source>Eur J Cancer</source>. <year>2007</year>;<volume>43</volume>(<issue>9</issue>):<fpage>1392</fpage>–<lpage>8</lpage>. Epub 2007/05/22. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ejca.2007.03.027" xlink:type="simple">10.1016/j.ejca.2007.03.027</ext-link></comment> <object-id pub-id-type="pmid">17512190</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Downey</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Akhurst</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Gonen</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Rusch</surname> <given-names>V</given-names></name>. <article-title>Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer</article-title>. <source>The Journal of thoracic and cardiovascular surgery</source>. <year>2007</year>;<volume>133</volume>(<issue>6</issue>):<fpage>1419</fpage>–<lpage>27</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jtcvs.2007.01.041" xlink:type="simple">10.1016/j.jtcvs.2007.01.041</ext-link></comment> <object-id pub-id-type="pmid">17532932</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Koo</surname> <given-names>HK</given-names></name>, <name name-style="western"><surname>Jin</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>CH</given-names></name>, <name name-style="western"><surname>Lim</surname> <given-names>HJ</given-names></name>, <name name-style="western"><surname>Yim</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>YT</given-names></name>, <etal>et al</etal>. <article-title>Factors associated with recurrence in patients with curatively resected stage I-II lung cancer</article-title>. <source>Lung Cancer</source>. <year>2011</year>;<volume>73</volume>(<issue>2</issue>):<fpage>222</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.lungcan.2010.11.013" xlink:type="simple">10.1016/j.lungcan.2010.11.013</ext-link></comment> <object-id pub-id-type="pmid">21168237</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pelosi</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Bille</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Skanjeti</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Errico</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Arena</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Ardissone</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Prognostic role of the PET parameter maximum standardized uptake value in non small cell lung cancer: analysis in tumour of diameter &gt;/ = and &lt;25 mm</article-title>. <source>Q J Nucl Med Mol Imaging</source>. <year>2011</year>;<volume>55</volume>(<issue>1</issue>):<fpage>72</fpage>–<lpage>80</lpage>. <object-id pub-id-type="pmid">20539268</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shiono</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Abiko</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Sato</surname> <given-names>T</given-names></name>. <article-title>Positron emission tomography/computed tomography and lymphovascular invasion predict recurrence in stage I lung cancers</article-title>. <source>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer</source>. <year>2011</year>;<volume>6</volume>(<issue>1</issue>):<fpage>43</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/JTO.0b013e3181f9abca" xlink:type="simple">10.1097/JTO.0b013e3181f9abca</ext-link></comment> <object-id pub-id-type="pmid">21079522</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kim</surname> <given-names>DH</given-names></name>, <name name-style="western"><surname>Son</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>CY</given-names></name>, <name name-style="western"><surname>Hong</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Oh</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Song</surname> <given-names>BI</given-names></name>, <etal>et al</etal>. <article-title>Prediction for recurrence using F-18 FDG PET/CT in pathologic N0 lung adenocarcinoma after curative surgery</article-title>. <source>Annals of surgical oncology</source>. <year>2014</year>;<volume>21</volume>(<issue>2</issue>):<fpage>589</fpage>–<lpage>96</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1245/s10434-013-3270-5" xlink:type="simple">10.1245/s10434-013-3270-5</ext-link></comment> <object-id pub-id-type="pmid">24046125</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Domachevsky</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Groshar</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Galili</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Saute</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Bernstine</surname> <given-names>H</given-names></name>. <article-title>Survival Prognostic Value of Morphological and Metabolic variables in Patients with Stage I and II Non-Small Cell Lung Cancer</article-title>. <source>European radiology</source>. <year>2015</year>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00330-015-3754-8" xlink:type="simple">10.1007/s00330-015-3754-8</ext-link></comment> <object-id pub-id-type="pmid">25929940</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ko</surname> <given-names>KH</given-names></name>, <name name-style="western"><surname>Hsu</surname> <given-names>HH</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>TW</given-names></name>, <name name-style="western"><surname>Gao</surname> <given-names>HW</given-names></name>, <name name-style="western"><surname>Cheng</surname> <given-names>CY</given-names></name>, <name name-style="western"><surname>Hsu</surname> <given-names>YC</given-names></name>, <etal>et al</etal>. <article-title>Predictive value of 18F-FDG PET and CT morphologic features for recurrence in pathological stage IA non-small cell lung cancer</article-title>. <source>Medicine</source>. <year>2015</year>;<volume>94</volume>(<issue>3</issue>):<fpage>e434</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/MD.0000000000000434" xlink:type="simple">10.1097/MD.0000000000000434</ext-link></comment> <object-id pub-id-type="pmid">25621697</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref055"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Motono</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Ueno</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Tanaka</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Machida</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Usuda</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Sakuma</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Differences in the prognostic significance of the SUVmax between patients with resected pulmonary Adenocarcinoma and squamous cell carcinoma. Asian Pacific journal of cancer prevention</article-title>: <source>APJCP</source>. <year>2014</year>;<volume>15</volume>(<issue>23</issue>):<fpage>10171</fpage>–<lpage>4</lpage>. <object-id pub-id-type="pmid">25556443</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref056"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Park</surname> <given-names>SY</given-names></name>, <name name-style="western"><surname>Cho</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>WS</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>CY</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>JG</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>DJ</given-names></name>, <etal>et al</etal>. <article-title>Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer</article-title>. <source>Journal of nuclear medicine: official publication, Society of Nuclear Medicine</source>. <year>2015</year>;<volume>56</volume>(<issue>1</issue>):<fpage>45</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2967/jnumed.114.147561" xlink:type="simple">10.2967/jnumed.114.147561</ext-link></comment> <object-id pub-id-type="pmid">25525185</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref057"><label>57</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shimizu</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Maeda</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Yukawa</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Nojima</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Saisho</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Okita</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma</article-title>. <source>World journal of surgical oncology</source>. <year>2014</year>;<volume>12</volume>:<fpage>343</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1477-7819-12-343" xlink:type="simple">10.1186/1477-7819-12-343</ext-link></comment> <object-id pub-id-type="pmid">25392182</object-id>; PubMed Central PMCID: PMC4254182.</mixed-citation></ref>
<ref id="pone.0146195.ref058"><label>58</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yoo</surname> <given-names>Ie R</given-names></name>, <name name-style="western"><surname>Chung</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>HL</given-names></name>, <name name-style="western"><surname>Choi</surname> <given-names>WH</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>YK</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>KY</given-names></name>, <etal>et al</etal>. <article-title>Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis</article-title>. <source>Bio-medical materials and engineering</source>. <year>2014</year>;<volume>24</volume>(<issue>6</issue>):<fpage>3091</fpage>–<lpage>103</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3233/BME-141131" xlink:type="simple">10.3233/BME-141131</ext-link></comment> <object-id pub-id-type="pmid">25227018</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref059"><label>59</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vaidya</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Creach</surname> <given-names>KM</given-names></name>, <name name-style="western"><surname>Frye</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Dehdashti</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Bradley</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>El Naqa</surname> <given-names>I</given-names></name>. <article-title>Combined PET/CT image characteristics for radiotherapy tumor response in lung cancer</article-title>. <source>Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology</source>. <year>2012</year>;<volume>102</volume>(<issue>2</issue>):<fpage>239</fpage>–<lpage>45</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.radonc.2011.10.014" xlink:type="simple">10.1016/j.radonc.2011.10.014</ext-link></comment> <object-id pub-id-type="pmid">22098794</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref060"><label>60</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tixier</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Hatt</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Valla</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Fleury</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Lamour</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Ezzouhri</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Visual Versus Quantitative Assessment of Intratumor 18F-FDG PET Uptake Heterogeneity: Prognostic Value in Non-Small Cell Lung Cancer</article-title>. <source>Journal of nuclear medicine: official publication, Society of Nuclear Medicine</source>. <year>2014</year>;<volume>55</volume>(<issue>8</issue>):<fpage>1235</fpage>–<lpage>41</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2967/jnumed.113.133389" xlink:type="simple">10.2967/jnumed.113.133389</ext-link></comment> <object-id pub-id-type="pmid">24904113</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref061"><label>61</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kang</surname> <given-names>SR</given-names></name>, <name name-style="western"><surname>Song</surname> <given-names>HC</given-names></name>, <name name-style="western"><surname>Byun</surname> <given-names>BH</given-names></name>, <name name-style="western"><surname>Oh</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>HS</given-names></name>, <name name-style="western"><surname>Hong</surname> <given-names>SP</given-names></name>, <etal>et al</etal>. <article-title>Intratumoral Metabolic Heterogeneity for Prediction of Disease Progression After Concurrent Chemoradiotherapy in Patients with Inoperable Stage III Non-Small-Cell Lung Cancer</article-title>. <source>Nuclear medicine and molecular imaging</source>. <year>2014</year>;<volume>48</volume>(<issue>1</issue>):<fpage>16</fpage>–<lpage>25</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s13139-013-0231-7" xlink:type="simple">10.1007/s13139-013-0231-7</ext-link></comment> <object-id pub-id-type="pmid">24900134</object-id>; PubMed Central PMCID: PMC4035157.</mixed-citation></ref>
<ref id="pone.0146195.ref062"><label>62</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cook</surname> <given-names>GJ</given-names></name>, <name name-style="western"><surname>Yip</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Siddique</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Goh</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Chicklore</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Roy</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?</article-title> <source>Journal of nuclear medicine: official publication, Society of Nuclear Medicine</source>. <year>2013</year>;<volume>54</volume>(<issue>1</issue>):<fpage>19</fpage>–<lpage>26</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2967/jnumed.112.107375" xlink:type="simple">10.2967/jnumed.112.107375</ext-link></comment> <object-id pub-id-type="pmid">23204495</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref063"><label>63</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Boellaard</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Krak</surname> <given-names>NC</given-names></name>, <name name-style="western"><surname>Hoekstra</surname> <given-names>OS</given-names></name>, <name name-style="western"><surname>Lammertsma</surname> <given-names>AA</given-names></name>. <article-title>Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study</article-title>. <source>Journal of nuclear medicine: official publication, Society of Nuclear Medicine</source>. <year>2004</year>;<volume>45</volume>(<issue>9</issue>):<fpage>1519</fpage>–<lpage>27</lpage>. <object-id pub-id-type="pmid">15347719</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref064"><label>64</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stahl</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ott</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Schwaiger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Weber</surname> <given-names>WA</given-names></name>. <article-title>Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET</article-title>. <source>European journal of nuclear medicine and molecular imaging</source>. <year>2004</year>;<volume>31</volume>(<issue>11</issue>):<fpage>1471</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00259-004-1626-6" xlink:type="simple">10.1007/s00259-004-1626-6</ext-link></comment> <object-id pub-id-type="pmid">15257418</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref065"><label>65</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Weerasuriya</surname> <given-names>DK</given-names></name>, <name name-style="western"><surname>Lavori</surname> <given-names>PW</given-names></name>, <name name-style="western"><surname>Quon</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Hara</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Maxim</surname> <given-names>PG</given-names></name>, <etal>et al</etal>. <article-title>Metabolic tumor burden predicts for disease progression and death in lung cancer. International journal of radiation oncology, biology</article-title>, <source>physics</source>. <year>2007</year>;<volume>69</volume>(<issue>2</issue>):<fpage>328</fpage>–<lpage>33</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ijrobp.2007.04.036" xlink:type="simple">10.1016/j.ijrobp.2007.04.036</ext-link></comment> <object-id pub-id-type="pmid">17869659</object-id>.</mixed-citation></ref>
<ref id="pone.0146195.ref066"><label>66</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Machtay</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Duan</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Siegel</surname> <given-names>BA</given-names></name>, <name name-style="western"><surname>Snyder</surname> <given-names>BS</given-names></name>, <name name-style="western"><surname>Gorelick</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Reddin</surname> <given-names>JS</given-names></name>, <etal>et al</etal>. <article-title>Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial</article-title>. <source>Journal of clinical oncology: official journal of the American Society of Clinical Oncology</source>. <year>2013</year>;<volume>31</volume>(<issue>30</issue>):<fpage>3823</fpage>–<lpage>30</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2012.47.5947" xlink:type="simple">10.1200/JCO.2012.47.5947</ext-link></comment> <object-id pub-id-type="pmid">24043740</object-id>; PubMed Central PMCID: PMC3795891.</mixed-citation></ref>
</ref-list>
</back>
</article>